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Abstract 
Breast cancer is the most prevalent organ-specific cancer in women world-wide. Angiogenesis 
is the formation of new blood vessels from pre-existing ones. This biological process plays a 
major role in tumor metastasis and progression. Small RNA molecules (microRNAs or 
miRNAs) are found to regulate tumor metastasis and can be identified in the body fluids.  
The first thesis manuscript (2nd chapter), investigated the roles of miR-526b and miR-655 in 
breast cancer-associated angiogenesis. Here, I measured the mRNA expression of known 
angiogenesis and lymphangiogenesis markers in the miRNA overexpressed breast cancer cell 
lines. The roles of both miRNAs on human umbilical vein endothelial cell (HUVEC) functions, 
using conditioned media collected from the cancer cell lines were also tested. The results show 
that both miRNAs promote the upregulation of angiogenesis and lymphangiogenesis ligands, 
VEGFA, VEGFC, VEGFD and the vascular growth factor receptors, VEGFR1 & VEGFR2 at 
mRNA level. Moreover, the cell-free conditioned media from the miRNA overexpressed 
cancer cells promote migration and tube formation of HUVEC in vitro via EP4 activation. 
Hence, both miRNAs regulate tumor growth and paracrine stimulation of angiogenesis in 
breast cancer.  
Moreover, we have previously shown that miR-526b and miR-655 are significantly high in 
human breast tumors and correlate with poor patient survival. However, these two miRNAs 
were never tested in human blood plasma. The second manuscript (3rd chapter), tested the 
expression levels of pri-miR526b and pri-miR655 in the blood plasma of breast cancer patients 
and benign candidates with no evidence of disease (control). Results show that pri-miRNA in 
plasma are significantly high in breast cancer than the control. Also, both pri-miRNAs can 
differentiate tumor stages and associates with diagnostic parameters in breast cancer. This 
suggests the potential of these pri-miRNAs as a blood-based biomarker in breast cancer. 
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CHAPTER 1 
Introduction 
1.1 Cancer as a Global Disease 
Globally, cancer has emerged as the second leading cause of death, after cardiovascular 
diseases. About 27 million new cancer cases and 17.5 million cancer deaths are estimated  by 
the year 20501. In Canada, cancer is the leading cause of death, causing about 30% of all deaths. 
Among organ-specific cancers, breast cancer is the most prevalent, causing an average of 14 
deaths per day among women in Canada. However, statistics show an increasing rate of cancer 
survivors with early detection of cancer2, emphasizing the importance of studies on strategies 
for early detection of breast cancer. 
1.2 Breast Cancer Overview 
Breast cancer is a complex disease, more commonly found in women than men. In 
Canada, 26,300 breast cancer cases were diagnosed among women and 230 cases among men 
in the year 20172. Presently, this disease is ranked as the second deadly disease among 
Canadian women. Breast cancer is a heterogeneous disease, arising from different cells and 
tissues that make up the organ. About 95% of all breast cancer types are of epithelial origin. 
They arise from the epithelial cells of breast lobules and ducts to form malignant tumors3. 
Tumors consist of a mass of cells within tissues that grow uncontrollably due to the loss of 
cellular regulation of growth. Tumor cells have the potential of migrating from one tissue to 
another, invading the surrounding tissues and distant organs. Clinically, breast cancer is 
classified into two main groups: localized carcinomas (in-situ) and invasive carcinomas4. In 
carcinoma in-situ, the tumor cells are confined within the breast duct or lobules. In contrast, 
invasive carcinomas are characterized with the dissemination of the tumor cells from the breast 
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to other organs. The tumor cells travel and settle in secondary sites to grow into another tumor 
by a biological process known as metastasis.  
Metastasis is a hallmark of invasive breast cancer and correlates with poor patient outcome. 
This cancer phenotype is measured by the level of disruption of tissue margins and tumor cell 
invasion. Metastatic breast cancer is classified using tumor staging techniques. The stage of 
breast cancer is determined by measuring the tumor size (T), regional lymph node involvement 
(N) and/or the metastasis (M) to other organs. Presently, the T-N-M based classification of 
tumors is the gold standard for breast tumor staging, and highest survival rate is seen in early 
tumor stages5 (Table 1-1). 
 
Primary Tumor (T)        Descriptions 
T0        No evidence of primary tumor 
Tis        Carcinoma in situ 
T1, T2, T3, T4      Increasing size and/or local extension of 
                                                                                    the primary tumor 
N0        No regional lymph node metastases 
N1, N2, N3      Increasing number or extent of regional 
Table 1-1 Tumor-Nodal-Metastasis Classification for Breast Cancer 
Stages TNM Class 5 Year Survival 
Prognosis 
 
Stage 0 
 
Tis, N0, M0 
 
93% 
 
Stage 1 
 
T1, N0, M0 
 
88% 
 
Stage 2a 
Stage 2b 
 
T0 or T1, N1, M0 or T2, N0, M0 
T2, N1, M0 or T3, N0, M0 
 
74 – 81 % 
 
Stage 3a 
Stage 3b 
Stage 3c 
 
T0-T2, N2, M0 or T3, N1 or N2, 
M0 
T4, N0-N2, M0 
T, N3, M0 
 
41 – 67% 
 
Stage 4 
 
Any T, N, and M1 
 
15% 
3 
 
                                                                                    lymph node involvement 
M0        No distant metastases 
M1        Distant metastases present 
Table 1-1: Shows the TNM Classification of Breast Cancer Disease Stages6 
1.2.1 Gene Expression and Subtypes of breast cancer 
Gene expression profiling of breast tumors divide the disease into five major breast 
cancer subtypes based on the expression of three receptors, namely: estrogen receptor (ER), 
progesterone receptor (PR) and human epidermal growth factor receptor-2 (HER-2) (Table 1-
2)7. Most breast cancer patients belong to the Luminal-A biological subtype, making up about 
60% of all breast cancer subtypes according to their hormonal and HER-2 receptor status8. 
Table 1-2 Breast Cancer Subtypes and their Hormonal Receptor Status 
Subtype Receptor Status 
Luminal A ER+ve PR+ve HER2-ve (50-60%) 
Luminal B ER+ve PR+ve HER2-/+ve (15-20%) 
HER2+ ER-ve PR-ve HER+ve (15-20%) 
Basal-like ER-ve PR-ve HER2-ve (8-37%) 
Normal-like ER+/-ve PR+/-ve HER2-ve (5-10%) 
 
The complexity of multiple breast cancer subtypes has made treatment very difficult. Presently, 
targeted treatments are used for breast cancer treatment at the clinic. Hence, treatment is 
specific to individual breast cancer subtype. Hormonal and HER-2 receptor status of the 
patients are the primary markers needed to start individualized treatments. The estrogen 
receptor-α (ERα) is found in about 70-80% of all breast cancer subtypes. At the clinic, ER 
alpha positive patients receive a specific estrogen receptor inhibitor therapy, Tamoxifen, to 
stop growing tumors. Tamoxifen works by binding the estrogen receptors, preventing 
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subsequent activation of the receptor 9. Trastuzumab is another target-specific drug for breast 
cancer treatment. It is a monoclonal antibody that targets the extracellular domain of the HER-
2 receptor and inhibits the activation of tyrosine kinase domain. Patients with HER-2 receptor 
expressions have been effectively treated with Trastuzumab10. However, 70% of breast cancer 
patients are HER-2 negative, and thus are urgently in need of new therapeutic targets. The 
breast cancer subtype which lacks expression of all three receptors (ER, PR, HER-2) is 
classified as the basal subtype and is also known as the triple negative breast cancer11.   
1.2.2 Breast Cancer Detection 
Routine screening methods for breast examination starts with self-breast examination 
followed by clinical breast check with mammography. This breast examination allows 
Canadian women to go for formal screening only at the age of 50 years, followed by biopsy. 
Both clinical procedures are very painful and invasive. Mammographic examination exposes 
the breast to minimally painful compression and a low dose of radiation. The use of 
mammography for the early detection of breast tumors is flawed with false positive and false 
negative results. False positive mammograms exposes women to unnecessary invasive biopsies 
and open surgeries12. Recently, biological macromolecules (RNA, protein) have emerged as 
good prognostic and predictive tools in cancer diagnosis, referred to as tumor markers. They 
are overexpressed in malignant or invasive cancers and correlate with the disease progression13. 
Tumor markers are clinically categorized into tissue and serum markers based on the way in 
which they are assayed. These markers are clinically useful in preventing, screening and 
monitoring the treatment of breast cancer. Specifically, serum tumor markers are mostly used 
as detecting, predicting and monitoring tools in cancer diagnosis and treatment14. According to 
the American Society of Clinical Oncology (ASCO), clinically useful serum and tissue tumor 
markers in breast cancer include: Carbohydrate Antigen 15-3 (CA 15-3), Carcinoembryonic 
antigen (CEA), Estrogen receptor (ER), Progesterone receptor (PR), Human epidermal growth 
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factor receptor 2 (HER2), Urokinase plasminogen activator (uPA) and Plasminogen activator 
inhibitor 1 (PAI-1)15. Hormonal markers from tissue biopsies are only relevant for prognosis 
and prediction of disease outcome. Presently, serum tumor markers including CA15-3, are 
routinely used for breast cancer screening at the clinic. However, they show low sensitivity 
(10-15%) in detecting early stages of breast cancer16. Hence, they are not effective biomarkers 
for the early detection of cancer. This emphasizes the need for a more sensitive, tissue-specific, 
and less invasive biomarker for the early detection of breast cancer.  
1.3 Tumor-Associated Angiogenesis  
Angiogenesis is the formation of new blood vessels from pre-existing vessels. It is a 
complex cellular process involving a cascade of endothelial cell proliferation, sprouting, 
migration and tube-formation. Angiogenesis and lymphangiogenesis share similar cellular 
processes and are essential for homeostasis. Dr. Judah Folkman’s proposition for cancer 
progression reveals that every solid tumor can only grow beyond 2mm when they are 
accompanied by blood vessel17. Thus, a growing tumor is limited by the absence of 
accompanying blood vessels that supplies it with oxygen and nutrients. Tumors overcome this 
limitation by switching on biological mechanisms for angiogenesis, used for its dissemination 
and progression. Tumor-associated angiogenesis is initiated by attracting vascular endothelial 
cells (ECs) from pre-existing vasculatures to form new blood vessels within the tumor 
interstitial space, referred to as the tumor microenvironment18.  
1.3.1 Mechanism of Angiogenesis 
The growth of new capillary vessels from pre-existing ones is called sprouting 
angiogenesis. The main function of these vessels is to supply oxygen and nutrients as well as 
remove metabolic wastes from growing tissues and organs. Sprouting angiogenesis is a primary 
mechanism used by  tissues to regulate physiological conditions such as wound healing and 
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other processes associated with malignancies and cancer19. Tumor-associated angiogenesis is 
initiated by the hypoxic condition in avascular tumor mass. Hypoxia induces the activation of 
matrix metalloproteinases (MMPs), including MMP-9, to breakdown the extracellular matrix 
and basement membrane surrounding the endothelial cells20. The breakdown of the 
extracellular matrix also releases vascular endothelial growth factors (VEGFs) to activate the 
growth and migratory capacity of endothelial cells. VEGF activates endothelial cells by binding 
to their cognate vascular endothelial growth factor receptors (VEGFR) on ECs. The ECs align 
and branch out into tube-like networks of unspecialized vessels during their migration in 
response to growth factors. The response of ECs to VEGFs stimulants determine the direction 
of the newly sprouting vessel21.  
1.3.2 Lymphangiogenesis 
Lymphatic vessels form the second main route of the vascular system. In contrast to 
blood vascular channels, the lymphatics form a network of capillaries, collecting vessels and 
ducts which sieves lymphocytes and drains the lymph fluids from the extravasated spaces back 
to the systemic circulation22. Metastasis of cancer cells to the regional lymph nodes is an 
indicator of lymphatic involvement in tumor progression. In breast cancer, the lymphatic 
channels form one of the main routes of metastasis23. Pro-lymphangiogenic factors, including 
VEGF-C, have been shown to promote lymphangiogenesis in breast cancer metastasis24. 
1.3.3 Angiogenic Factors  
Vascular endothelial growth factor (VEGF) otherwise called vascular permeability 
factor (VPF), forms the principal group of pro-angiogenic factors involved in tumor-associated 
angiogenesis. They essentially play the role of activating proliferation and migration of 
endothelial cells (ECs) in the extracellular matrix. Angiogenesis and lymphangiogenesis are 
controlled by the active interaction of the VEGF ligands with three basic VEGFRs (VEGFR1-
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3). The VEGF family is made up of 6 growth factor members including, VEGF-A, VEGF-B, 
VEGF-C, VEGF-D, VEGF-E and placental growth factor (PlGF). They all interact differently 
with their respective cognate VEGFRs25. VEGFRs are tyrosine kinase receptors which are 
activated by the dimerization of adjacent VEGFR molecules. This molecular event stimulates 
the phosphorylation of intracellular tyrosine in the tyrosine kinase domain. However, this event 
is dependent upon the binding interaction between the VEGF and VEGFR26. VEGFR-1 is 
typically expressed on the endothelial cells (ECs) lining the blood vessels but lacks expression 
on the lymphatic endothelial cells (LEC). VEGFR-2 is also well expressed on the ECs and 
weakly expressed on LECs. However, the LEC strongly express VEGFR-3, serving as a typical 
expression marker for lymphangiogenesis27. 
VEGF-A is a ligand expressed by both tumor and healthy cells. It is the most potent pro-
angiogenic factor and stimulate angiogenesis by binding to transmembrane VEGFR-1 and 
VEGFR-2 receptors on ECs. This molecular interaction activates the proliferation, survival and 
migration of ECs for new blood vessel formation. It was formally thought that VEGF-A is only 
specific for angiogenesis. However, VEGF-A has been shown to activate the proliferation of 
LECs, which leads to lymphatic metastasis28. VEGF-C and VEGF-D are pro-lymphangiogenic 
factors associated with lymphangiogenesis and they bind VEGFR2 and VEGFR3 respectively. 
However, both VEGF-C and VEGF-D bind VEGFR3 to activate extracellular-signal-regulated 
kinase 1 or 2 (ERK1 or ERK2) and phosphorylates protein kinase B (PKB, otherwise known 
as AKT) in LEC proliferation, survival and migration29. In contrast, VEGF-B lacks pro-
angiogenic potential in vivo30. 
1.3.4 Angiogenesis Assays 
The methods used to demonstrate angiogenesis are based on the molecular events of 
the process. Different functional behaviors of vascular endothelial cells in angiogenesis can be 
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tested using in vitro and in vivo angiogenesis assays. The human umbilical vein endothelial 
cells (HUVEC) are typical cell culture models used for in vitro angiogenesis studies31. Mainly, 
angiogenesis can be functionally demonstrated in vitro using two methods, endothelial cell 
migration assays and endothelial tube formation assays. 
1.3.4.1 Endothelial Cell Migration Assays 
This assay is otherwise called the “wound healing” or “scratch-wound” assay. It is one 
of the simplest and reliable assays for assessing endothelial cell function in vitro. It is a 
relatively cheap and simple assay that models 2-dimentional EC migration. This assay assesses 
the migration potential of ECs by measuring the healing rate of a scratch made through a 
monolayer of ECs. The migration of the ECs across the scratched surface is measured on a 
time-point basis. This assay is very rapid and can be used to observe angiogenesis continuously. 
However, the level of confluency of ECs, variations in scratch sizes and arbitrary quantification 
styles exposes this method to bias. Recently, studies show that the use of stencils overcomes 
the bias due to scratched sizes32. 
1.3.4.2 Endothelial Cell Tube Formation Assays 
The assessment of the native tube-forming potential of ECs on extracellular matrix is 
among the most specific test for angiogenesis. This assay simulates new vasculature formation 
in vitro by the tube formation of vascular ECs on a petri dish coated with Matrigel (artificial 
extracellular matrix). The modeling of near-in vivo angiogenesis is an advantage of this assay 
over other in vitro assays. However, this assay demonstrates homogenous tubes and does not 
show the in vivo situation of tube varieties. Nevertheless, it is rapid, sensitive and reliable33. 
Matrigel is a jelly-like product made from Engelbreth–Holm–Swarm (EHS) mouse tumor cells. 
It is principally made of laminins and collagens and is used to simulate the extracellular matrix 
in vitro. The tube formation assay is carried out by seeding the ECs on Matrigel and monitoring 
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the tubes formed at different time points. Using this assay, angiogenesis can be measured by 
quantifying the number or length of the tubes and branch-points formed by the ECs34.  
1.3.4.3 In vivo Angiogenesis Assays 
The in vivo assays of angiogenesis demonstrate all the steps of the angiogenesis process 
using a whole living system as models. Many animal models are used to assay angiogenesis in 
vivo. They demonstrate functional vascular network which are characteristic of the normal and 
disease states of the animal32. The in vivo assays of angiogenesis include the chick 
chorioallantoic membrane (CAM) assay, corneal angiogenesis assay, and the Matrigel plug 
assay, which are developed to measure pro- and anti-angiogenic factors35. Due to the 
transparency of zebrafish embryos during early developmental stages, it is emerging as a 
popular model for in vivo assessment of angiogenesis36. Recently we have shown that 
prostaglandin E2 (PGE2) promotes vascular maturation and angiogenesis using Zebrafish as 
an in vivo model37 (Figure 1-1).  
 
Figure 1-1: In vivo model of Angiogenesis showing zebrafish trunk vasculature development 
at different time-points37. 
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1.4 MicroRNA and Breast Cancer 
MicroRNAs (miRNAs or miRs) are short (approx. 22 bps), non-coding, single-
stranded, RNA molecules that regulate gene expressions at the post-transcriptional level in 
eukaryotes, including humans38. Biogenesis of miRNAs starts with the transcription of primary 
miRNA (pri-miRNA) by RNA Polymerase III in the nucleus. The pri-miRNA is further 
processed by DiGeorge critical region 8 (DGCR8) microprocessor in association with by 
ribonuclease III enzyme (Drosha) to form the precursor miRNA (pre-miRNA). Pre-miRNAs 
are characterized with imperfect base-pairs which fold to form a stem-loop hairpin structure. 
At this stage, the pre-miRNAs are exported out of the nucleus into the cytoplasm by exportin-
5 to be cleaved into a double stranded RNA (dsRNA) duplex by an endonuclease called Dicer. 
Mature miRNA sequence is a complement strand of the dsRNA duplex and is guided by the 
miRNA-associated RNA-induced silencing complex (miRISC) and the Argonaute protein 
(Ago2), to the target-specific sequences on the messenger RNA (mRNA). The mature miRNA 
specifically binds their target protein coding sequences on mRNA to repress gene expressions. 
The complete or incomplete complementarity of the base paring between the mature miRNA 
and the target mRNA sequence results in a reduced or complete loss of gene expression39 
(Figure 1-2).  
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Figure 1-2: Diagrammatic representation of miRNA Biogenesis and Target   Regulation of 
Gene Expression40. 
In humans, about 1917 miRNA sequences have been annotated in the miRbase and are 
associated with predicted and validated gene targets41. Most of them regulate key biological 
processes including cellular proliferation and differentiation42. Breast cancer patient poor 
outcome is increased by metastasis of the tumor cells to other organs of the body. Metastasis 
contributes up to 90% of cancer mortality in organ-specific cancers, including breast cancer43. 
Recently, Majumder et al showed that aggressive breast cancer growth contributes to miRNA 
profiles44. Moreover, miRNAs show positive correlation with different steps of the breast 
cancer metastatic cascade, implicating them in breast cancer metastasis45. Gene expression 
analysis has identified circulating miRNAs as good candidates for predictive, prognostic and 
diagnostic biomarkers in breast cancer46.  
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1.5 miRNAs as Biomarkers 
Circulating miRNAs in human body fluids have shown oncogenic roles and positively 
correlate with cancer progression. Most oncogenic miRNAs show tissue specificity and 
aberrant expressions in cancers. miRNAs are stable in human blood plasma/serum and can be 
assayed as biomarkers of choice for most invasive cancers47. The ease of detecting miRNAs 
across disease stages in circulating body fluids, qualify them as disease screening tools at the 
clinic48. Both total RNAs and miRNAs expressions can be quantified with precision using high-
throughput techniques. Quantitative real time PCR (qRT-PCR) is considered as a gold standard 
for the quantification of nucleic acid expression. This technique measures RNA based on the 
starting amount of the test sample and the quantity of amplicons at a cycle number49. The qRT-
PCR procedure starts with the isolation of RNA sample, followed by a reverse transcription 
reaction to synthesize a complementary DNA (cDNA) strand for quantification of gene 
expressions. Analysis of miRNA expression is done by the amplification and quantification of 
cDNA in real-time. This technique was previously limited by the short sizes of miRNAs; 
however, this challenge was defeated with the advent of specific primers and probe designs. 
The quantification of miRNA expressions can either be done by absolute or relative methods. 
In the relative quantification method, endogenous controls are used to correct variabilities due 
to starting amounts of the DNA template and enzyme efficiencies in qRT-PCR. The advantage 
of qRT-PCR over other techniques is its sensitivity in quantifying both low and high amounts 
of RNA50. 
1.6 Thesis Rationale 
Breast cancer is the leading cause of death among Canadian women. About 30-40% of 
women developing the disease are younger than 50 years of age. Studies show that early 
diagnosis could save the lives of 98% of breast cancer patients2. The chemo/radio-resistance 
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and relapse of invasive breast cancers are believed to result from a minor cell subset called 
“stem-like cells” (SLC). COX-2 overexpression occurs in about half of breast cancer patients 
and promotes the SLC phenotype in human breast cancer through the activation of the PGE2 
receptor, EP451. Overexpression of COX-2 in MCF7 cells upregulates two miRNAs, miR-655 
and miR-526b, and both miRNAs target 13 tumor suppressor-like genes. Stable over-
expression of miR526b and miR655 in MCF7 (low miRNA, low COX, HER2-ve) and SKBR3 
(low miRNA, low COX-2, high HER2+ve) cell lines promotes cell migration, invasion and 
SLC phenotype. The knockdown of miR-526b and -655 in aggressive breast cancer cells 
reversed all phenotypes and functions via EP4/PI3K/AkT signaling. Moreover, therapy with 
EP4 antagonist (EP4A) has been shown to be non-toxic and exhibit profound SLC-reductive, 
anti-tumor, anti-angiogenic, anti-lymphangiogenic and anti-metastatic effects in a murine 
breast cancer model52, 53. However, whether the overexpression of both miRNAs in breast 
cancer cells has a role in breast cancer angiogenesis and lymphangiogenesis remains unknown.  
Both miRNAs are significantly high in tumor tissues compared to non-adjacent control tissues 
and correlate with poor patient survival54, 55. Oncogenic miRNAs are high in tumor tissues and 
mostly target tumor suppressor genes56. Importantly, miRNAs are stable and detectable in the 
body fluids of breast cancer patients and are of interest as cancer biomarkers57. Furthermore, 
there are reports on circulating miRNA as biomarkers for other solid tumors58, but less is 
known about miRNA’s roles as breast cancer blood biomarkers. Here, I propose to test 
miR526b and miR655’s role in tumor-associated angiogenesis and investigate their potential 
as biomarkers in breast cancer.  
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CHAPTER 2 
Role of miR526b and miR655 in Breast Cancer Angiogenesis 
2.1 Introduction 
Breast cancer is a heterogeneous disease arising from different tissues within the breast. 
It is the most prevalent organ-specific cancer, making up around 25% of all new cancer cases 
among Canadian women. Recent data show breast cancer as the one of the leading causes of 
death among women, second only to cardiovascular diseases. The diagnosis of this disease is 
essential in making treatment decisions, which relies on parameters such as hormone receptor 
status and gene expressions2, 59.  
Adenocarcinoma is the most common form of breast cancer, arising from the glandular 
epithelium of the breast. Malignant forms of breast cancer are very invasive and often 
metastasize to other organs of the body. About 90% of deaths from organ-specific cancers 
(including breast cancer) is associated with metastasis60. Metastatic breast cancer has poor 
disease prognosis, allowing the progression of cancer to spread to other organs. Metastasis 
starts with aggressive tumor growth, which leads to a change from epithelial to mesenchymal 
cell type, referred to as epithelial-to-mesenchymal transition (EMT)61. This cellular behavior 
gives the cancer cells the ability to invade the extracellular matrix and break cell-cell adhesions. 
EMT is described in vitro by a set of indices including the loss of epithelial cell polarity, 
individual cell separation and cell migratory behavior. This phenotype is induced by different 
growth factors, the most prominent being Transforming Growth Factor-Beta (TGF-β). It is also 
signaled through the cell survival pathways, including the P13K/NFϰB axis. Growth factors 
initiate the EMT phenotype in tumors by repressing cell-to-cell adhesion molecules, E-
cadherin, and upregulating mesenchymal transcription factors, including Snail-1 and 2, Zeb-1 
and 2, and Twist62, 63.  
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Mesenchymal behavior of malignant cells enables them to invade newly formed blood or 
lymphatic vessels. The intravasation of new blood vessels by malignant cancer cells, forms the 
second phase of the tumor metastatic cascade. Malignant cancer cells travel within the vascular 
channels as circulating tumor cells, then extravasate at distant organs to initiate secondary 
tumor growth. This migratory behavior of cancer cells is reported to be highly dependent on 
factors within the tumor interstitial space, called the microenvironment64, 65. The tumor 
microenvironment is largely made up of cancerous cells and non-cancerous cells. Non-
cancerous cells in tumor microenvironments are also known as stromal cells. They have been 
found to consist of cancer-associated fibroblasts (CAFs), tumor-associated macrophages 
(TAMs), endothelial cells, pericytes, and infiltrating immune cells. Stromal cells are recruited 
to the tumor site by chemokines and growth factors produced by the tumor cells. Endothelial 
cells are believed to communicate with the tumor cells using this mechanism to promote tumor 
growth and metastasis. Altogether, the cancerous, non-cancerous and circulating tumor cells 
produce microRNAs (miRNA), which they use to regulate cell communication, migration and 
tumor growth66.  
2.2 miR526b and miR655 are Oncogenic miRNAs 
MicroRNAs (miRNAs) are small non-protein coding RNAs that negatively regulate 
target gene expressions at post-transcriptional level. They regulate gene expressions by 
complete or partial complementary base paring of mature miRNAs on specific sequences of 
the messenger RNA (mRNA)67. Oncogenic miRNAs are found in the tumor 
microenvironments and have recently emerged as vital players in the regulation of tumor 
growth and progression68. With the combined gene and miRNA expression array, Majumder 
et al reported that overexpression of COX-2 upregulates miR526b and miR655 in human breast 
cancer. Both miR526b and miR655 are expressed in the same miRNA cluster located on 
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chromosome 19 in humans and target 13 tumor suppressor genes in human breast cancer. A 
total of 6 out of the 13 suppressor genes were downregulated by both miRNAs and the 
phosphatase and tensin homolog, (PTEN) was identified as a common target of both miRNAs63, 
69, 70. PTEN is a known tumor suppressor and a negative regulator of the PI3K/Akt cell 
signaling pathway in breast cancer. The decreased expression of PTEN correlates with 
aggressive cell functions and poor prognosis in breast cancer71. The expression of miR526b 
and miR655 is significantly high in malignant breast tumor and is associated with poor patient 
survival. The stable overexpression of both miRNAs in poorly metastatic MCF7 breast cancer 
cells (low miRNA, low COX, HER2-ve), promotes primary tumor growth, EMT, migration, 
invasion, and metastasis through the EP4/PI3K/AkT signaling pathway (Figure 2-1). 
Moreover, EP4 antagonist showed an anti-metastatic and miRNA-inhibitory effect in different 
breast cancer models63, 69, 70. These miRNA-induced phenotypes suggest their involvement in 
breast cancer progression. However, the involvement of both miR526b and miR655 in the 
cellular mechanism of breast cancer-associated angiogenesis has not been studied.  
 
Figure 2-1: Roles of miR526 and miR655 in human breast cancer progression72 
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2.3 Tumor-Associated Angiogenesis 
Angiogenesis is the process of forming new blood vessels from pre-existing 
vasculatures in the tissue. It is a basic part of the normal biological processes involved in 
physiological development, reproduction and wound repair. However, angiogenesis is 
implicated as a vital step in cancer metastasis73. Previously, Judah Folkman showed 
angiogenesis as a key biological mechanism used by tumors to sustain their growth and 
progression74. Tumors retard in growth and form a necrotic core when blood vessels are greater 
than 2mm in distance away from them. This behavior makes it difficult for tumors to grow 
beyond 2mm without accompanying blood vessels. Thus, a sustained supply of essential 
nutrients and oxygen for tumor cell growth is dependent on the formation of new blood vessels. 
The mechanism of angiogenesis is a complex process involving the interaction of many 
angiogenic molecules and cellular receptors. The foremost molecular players involved in the 
angiogenesis process is the VEGF family and their cognate receptors, known as VEGFRs 75. 
VEGFs are highly secreted by tumor cells in low oxygen states. Importantly, the transcription 
factor, hypoxia-inducing factor (HIF)-1α is induced by low oxygen tension within the tissues 
and associated with increased VEGF secretion in solid tumors76. VEGFRs are highly expressed 
on the endothelial cells, which allows the VEGFs to act almost exclusively on endothelial cells. 
The binding of VEGFs to VEGFRs on endothelial cells initiates the intracellular signaling 
sequence that modulates the genes for endothelial cell proliferation and migration in 
angiogenesis. Primarily, VEGF-A mediates angiogenesis by binding to VEGFR-1 and 
VEGFR-2. This ligand-receptor interaction leads to proangiogenic activity and migration of 
endothelial cells in the extracellular matrix for new blood vessel formation75. This tumor-
associated regulation of endothelial cell proliferation and migration by secreting VEGFs into 
the tumor milieu is known as paracrine regulation. Furthermore, tumor cells also overexpress 
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the VEGFRs on their cell surfaces to self-regulate their growth and angiogenesis in a process 
referred to as autocrine regulation. The autocrine regulation of tumor-associated angiogenesis 
is demonstrated by the angiogenesis mechanism known as vascular mimicry in breast cancer77. 
Tumor cells initiate the paracrine regulation of angiogenesis by secreting VEGFs to bind to 
VEGFRs on endothelial cells for new blood vessel formation at the tumor site.  VEGFs (also 
called vascular permeability factors) bind to VEGFRs to mediate the hyperpermeability of 
endothelial cells in the tumor microenvironment, thereby releasing fibrin (a plasma protein) 
into the extracellular matrix to facilitate endothelial cell migration78, 79. The tissue 
transglutaminase activates the cross-linking of fibrin and promotes the deposition of collagen 
into the extracellular matrix, used for cell migration in tumor-associated angiogenesis80(Figure 
2-2). Moreover,  the interstitial fluid component of the tumor milieu is also made up of soluble 
proteins, growth factors and cytokines that form the tumor cell secretome involved in tumor 
metastasis81.       
 
Figure 2-2: The initiating mechanism of tumor-associated angiogenesis78 
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2.4 Objectives 
Hypothesis 1: miR526b and miR655 promote angiogenesis in human breast cancer (Figure 2-
3). 
This will be tested with miRNA low and high breast cancer cell lines to measure mRNA 
expression of angiogenesis markers. 
Hypothesis 2: miR526b and miR655 promotes vascular endothelial cell migration and tube 
formation in vitro (Figure 2-3). 
This will be tested using conditioned media from miRNA low and high cancer cells on human 
umbilical vein endothelial cell (HUVEC) cells (in vitro model) for two objectives: 
Objective 1: miRNA promotes HUVEC migration in vitro 
Objective 2: miRNA promotes HUVEC tube formation in vitro 
 
Figure 2-3: Showing the flowchart of hypothesis and objectives of study 
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2.5 Material and Method 
2.5.1 Cell Line Culture 
Human breast cancer cell line MCF7 was purchased from American Type Culture 
Collection (ATCC, Rockville, MD, USA). The MCF7 cell line expresses low levels of 
miR526b and miR655. It is estrogen receptor (ER) positive, HER-2 receptor negative and 
poorly metastatic in immune-deficient mice. Stable overexpressing MCF7-miR526b and 
MCF7-miR655 cell lines were derived by the transfection of MCF7 cells with miR-plasmids 
as previously described63, 70. All cancer cell lines which include MCF7, MCF7-miR526b and 
MCF7-miR655, were grown in Minimum Essential Medium (MEM) (GIBCO, ON), 
supplemented with 10% fetal bovine serum (FBS) and 1% Penstrep (complete media). The 
derived miRNA overexpressing cell lines, MCF7-miR526b and MCF7-miR655, were 
sustained with Geneticin (GIBCO, ON) at 200ng/mL. and supplemented with 0.4µl/ML human 
insulin (ATCC).  
The Human Umbilical Vein Endothelial Cell line (HUVEC) were purchased from Life 
Technologies and grown in complete Medium 200 (GIBCO, ON), supplemented with Low 
Serum Growth Supplement (LSGS) kit (GIBCO, ON) containing 2% FBS, hydrocortisone 
(1μg/mL), human epidermal growth factor (10ng/mL), basic fibroblast growth factor (3ng/mL), 
and heparin (10μg/mL). All cell lines were maintained in a humidified incubator at 37℃ 
temperature with 5% CO2. 
2.5.2 Collection of Conditioned Media 
MCF7, MCF7-miR526b and MCF7-miR655 cell lines were grown in complete MEM 
media until the cell culture was 95% confluent. Cell lines were washed with Phosphate 
Buffered Saline (PBS) to remove any trace of serum (containing cell growth factors). The cells 
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were then fed with only non-supplemented basal MEM (serum-free) for 12 hours prior to 
collection of the media, and then centrifuged. The cell-free supernatant (from all cancer cell 
lines) was collected and named as conditioned media and then tested during HUVEC cell 
functional assays. 
2.5.3 Drugs and Chemicals 
NS398 (COX-2 inhibitor) was purchased from Cayman Chemical (Michigan, USA); 
ONO-AE3-208 (selective EP4 antagonist) from ONO Pharmaceuticals, Osaka, Japan and 
Wortmannin (WM), an irreversible PI3K inhibitor purchased from Sigma-Aldrich. For all 
treatment conditions in vitro, 3% DMSO (used as drug vehicle) served as negative control. 
2.5.4 HUVEC Migration Assay 
Scratch-wound healing migration assay was conducted to study the paracrine effect of 
miR526b and miR655 on HUVEC migration. HUVEC cells were grown in a T75 flask, then 
harvested and re-suspended in the complete Medium 200. 300µL of the HUVEC suspension 
containing a concentration of 2×105/ml HUVEC cells were seeded into 24-well attachment 
plate and grown to 95% confluence. The surface of each well was scratched with a 2μl sterile 
micro-pipette tip in the middle and cells were washed with PBS to remove traces of serum. The 
line of scratch was marked to note the point of migration. To test HUVEC phenotype in serum-
starved media, 300μl of basal and serum-supplemented Medium 200 was added as the negative 
and positive controls respectively. To measure the migration stimulating capacities of the 
cancer cell conditioned media, 300μl of cell-free conditioned media collected from MCF7, 
MCF7-miR526b and MCF7-miR655 were added into three different wells per condition, to 
serve as three experimental replicates. The progress of HUVEC cell migration was monitored 
in a time-dependent order and images of the scratched wounds were captured using a Nikon 
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inverted microscope, at respective time intervals. ImageJ software was used to measure the 
width of the wounds in pixels. 
2.5.5 HUVEC Tube Formation Assay 
This assay was carried out with the 2nd, 3rd and 4th passages of HUVEC cell line on 
Growth Factor-Reduced (GFR) Matrigel under the same treatment conditions as stated above 
(HUVEC migration assay) and as adapted from Nandi et al, 201782. GFR Matrigel was thawed 
overnight at 4 °C, diluted with cold basal HUVEC media 200 in 1:1 ratio, and used to coat 24-
well culture plates (BD Biosciences, Mississauga, ON, Canada), 0.25 ml/well and left at 37 °C 
for 6hr. After polymerization, 40,000–50,000 cells/well were suspended in 300µl of non-
supplemented basal HUVEC media and serum-supplemented HUVEC and seeded in 3 wells 
per condition as experimental triplicates. Under native serum-free conditions and serum-rich 
conditions, very low levels and high levels of tubes/branch points were formed at 8hr time-
point, which gradually increased in a time-dependent manner to peak at 24hrs. These conditions 
served as negative controls and positive controls respectively. Both conditions were sustained 
for 48hrs, but they lost the phenotype of tube formation beyond 24hrs. To test the capacity of 
miR-526b and miR-655 to stimulate tube formation, conditioned media from MCF7, MCF7-
miR526b, and MCF7-miR655 cell lines was used to resuspend HUVEC in the same manner as 
above. Tube formation was examined at different time intervals, recorded from 0-24h and 
images of the tube network was captured with the Nikon inverted microscope. Quantification 
of tubes and branching points was carried out using NIH Image J software.  
2.5.6 MicroRNA Signaling Pathway   
Previously, Majumder et al showed that both miR-526b and miR-655 expressions in 
aggressive breast cancer were abrogated by inhibiting COX-2 or by blocking EP4 using EP4A. 
Both miRNA expressions were regulated via PI3K/Akt pathways63, 70. To test the involvement 
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of COX-2 and EP4 in miRNA induced cell migration, both HUVEC migration and tube 
formation assays were conducted in the presence of COX-2 inhibitor (COX-2-I), EP4 
antagonist (EP4A) and PI3K/Akt pathway inhibitor (WM) to test the involvement of the COX-
2 signaling pathway in miRNA-induced HUVEC functions.  300μl of cell-free conditioned 
media from MCF7-miR526b or MCF7-miR655 cell lines was used per condition, in addition 
with 20μM NS398 (COX-2-I), 50μM ONO-AE3-208 (EP4A), or 10μM WM (PI3K/Akt 
inhibitor) and maintained as described in both assays above. The solvent of the drugs, 3% 
DMSO, was used as vehicles to serve as the control. 
2.5.7 Real-time PCR 
Total RNA was extracted from MCF7, MCF7-miR526b and MCF7-miR655 cell lines 
using miRNeasy Mini Kit (Qiagen, ON) and reverse transcribed using the TaqMan microRNA 
and mRNA cDNA Reverse Transcription Kit (Applied Biosystems, USA). The TaqMan 
MiRNA or Gene Expression Assay was used for quantitative PCR. Beta-actin 
(Hs01060665_g1) and RPL5 (Hs03044958_g1) expressions were quantified using Realtime 
PCR (RT-PCR) and their cycle  threshold (CT) values were used to normalize the expressions 
of the following angiogenesis and lymphangiogenesis markers using relative gene expression 
analysis: VEGF-A (Hs00900055_m1), VEGF-C (Hs01099203_m1), FIGF (Hs01128659_m1), 
FLT-1 (Hs01052961_m1), KDR (Hs00911700), PTGS2 (Hs00153133_m1), and PTGER4 
(Hs00168761_m1). HUVECs grown to 90% confluency were treated overnight with 
conditioned media collected from MCF7-miR526b and MCF7-miR655 cell cultures. Total 
RNA was extracted from treated HUVECs and reverse transcribed to cDNA. TaqMan gene 
expression assay comparing the expression of VEGFR-1, VEGFR-2, and EP4 was conducted. 
Normalized expressions of the vascular markers, represented as delta CT (∆CT), were used to 
calculate the changes in vascular marker expressions between the control and test cell lines, 
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represented as delta-delta CT (∆∆CT) values and then, the fold-change (2-(∆∆CT)) gene 
expressions using the following formula83:  
Normalized Gene Expression (∆CT) = CT gene of interest – CT reference gene (actin) 
Delta-delta CT was then calculated using: 
∆∆CT = ∆CT gene of interest (MCF7-miRNA) - ∆CT gene of interest (MCF7) 
Fold-change was then calculated using: 
Fold-Change = 2-(∆∆CT) (This shows the doubling expression of the genes for each PCR cycle) 
2.5.8 Data Analysis 
Statistical calculations were performed using GraphPad Prism software version 5 
(GraphPad Software, CA, USA). All parametric data were analyzed with one-way ANOVA, 
followed by Student’s t-test, used to compare the means of two datasets. Statistically relevant 
differences between means were accepted at p < 0.05. 
2.6 Result 
2.6.1 Overexpression of miRNA in poorly metastatic breast cancer cell line (MCF7) 
upregulate angiogenesis marker expression  
We used MCF7 cell line to represent more than 50% of breast cancer patients who 
express estrogen receptor alpha on their tumor cells. To test for angiogenesis marker expression 
in MCF7 and miRNA-high MCF7 cell lines at the mRNA level, total RNA was extracted from 
95% confluent MCF7, MCF7-miR526b and MCF7-miR655 cell lines and reverse transcribed 
into cDNA for RT-PCR protocol. Relative gene expression analysis was performed to compare 
miRNA-high cell lines, MCF7-miR526b and MCF7-miR655 to MCF7 cells. RT-PCR 
quantification of COX-2, EP4 markers, and angiogenesis and lymphangiogenesis markers 
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VEGF-A, VEGF-C, VEGF-D, VEGFR-1, were found to be significantly upregulated in 
MCFmiR526b and MCF7-miR655 compared to the MCF7 cell line (Figure 2-4 A). Moreover, 
expression of receptors EP4 and VEGFR-1 were found to be significantly upregulated in 
MCF7-miR526b and MCF7-miR655 cell lines compared to MCF7 (Figure 2-4 B). The 
VEGFR-2 marker was observed to have a marginally higher expression in miRNA-high MCF7 
cell lines than the MCF7 cell line (Figure 2-4 B).  Moreover, receptor expression in HUVEC 
cells following the treatment with MCF7, MCF7-miR526b or MCF7-miR655 conditioned 
media was examined. By virtue, HUVECs show very high expression of VEGFR-1 and 
VEGFR-2; here, we observed that MCF7-miR526b and MCF7-miR655 conditioned media 
further induced expression, showing a significant upregulation of VEGFR-2 in comparison 
with HUVECs treated with MCF7 conditioned media (Figure 2-4C). Furthermore, expression 
of EP4 receptor was significantly upregulated in HUVECs treated with MCF7-miR526b or 
MCF7-miR655 conditioned media (Figure 2-4C). 
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Figure 2-4:  Overexpression of miR526b and miR655 in MCF7 or treatment of HUVECs with 
miRNA-conditioned media results in upregulation of angiogenesis and lymphangiogenesis 
ligand and receptor markers. (A) RT-PCR quantification of COX-2, angiogenic and 
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lymphangiogenic ligands, VEGF-A, VEGF-C, VEGF-D, show a significant positive fold-
change in MCF7-miR526b and MCF7-miR655 cell lines when compared with MCF7 cell line. 
(B) Quantitative RT-PCR analysis shows significant upregulation of EP4, and VEGFR-1, and 
marginal upregulation of VEGFR-2 expression in the MCF7-miR526b and MCF7-miR655 cell 
lines, when compared with MCF7. (C) Quantitative RT-PCR analysis shows the HUVECs 
treated with MCF7-miR526b or MCF7-miR655 conditioned media have greater receptor gene 
expression compared with HUVECs treated with MCF7 conditioned media. Figures A, B & C 
are shown in logarithmic scale since the gene expression fold changes for some markers are 
more than 1000-fold. So the MCF7 cells gene expression is equal to 1 (MCF7 = 1). RT-PCR 
quantitative data are presented as the mean ± SEM of three biological replicates; * p < 0.05, ** 
p < 0.01.  
2.6.2 miRNA conditioned media promotes HUVEC cell migration 
First, we conducted a scratch-wound migration assay to test HUVEC migration 
capacity in the presence and absence of growth factors. Here, we used complete (with growth 
factors) and basal (without growth factors) HUVEC media to serve as positive and negative 
control, respectively (Figure 2-5 A). To examine the paracrine potential of the miRNA-high 
cell lines secretions to induce angiogenesis, we conducted the same assay above, to test the cell 
migration capacity of HUVEC cells in the presence of cell-free conditioned media collected 
from miRNA-high and low MCF7 cell lines. Using this assay, we observed a significant 
increase in HUVEC cell migration with cell-free conditioned media collected from miRNA-
high (MCF7-miR526b and MCF7-miR655) cell lines compared to that of MCF7, in a time-
dependent manner (Figure 2-5 B, C). 
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Figure 2-5: Cell-free conditioned media from MCF7-miR526b and MCF7-miR655 cell lines 
promote cellular migration of HUVECs, in a time-dependent order. (A) Chart shows HUVEC 
phenotype in basal and complete HUVEC media at 0 and 24-hr time points. (B) Chart shows 
migration assay with conditioned media at 0, 4 and 24-hour time-points, with HUVECs 
migrating more in the conditioned media from MCF7-miR526b and MCF7-miR655 than the 
parental MCF7 (from dark to light blue). (C) Quantification of the wound width showed a 
significant difference in the wound sizes when treated with MCF7-miR526b and MCF7-
miR655 conditioned media compared to MCF7 conditioned media. Scratch-wound migration 
assays were conducted as three independent experiments and data presented as triplicate mean 
± SEM. * indicates p<0.05. 
2.6.3 miRNA Conditioned Media Promotes HUVEC Tube Formation  
To further show the paracrine effects of miR-526b and miR-655 on angiogenesis in 
vitro, I conducted a tube formation assay and tested the HUVEC phenotype in basal and 
complete HUVEC media as above (Figure 2-6 A). Tube formation assay on GFR Matrigel in 
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a Petri dish is an established surrogate of angiogenesis in vitro. HUVEC cells respond rapidly 
to angiogenic signals by aligning cell-to-cell to form branch points. They further differentiate, 
connecting with each other to form complete tubes or loops with a lumen bounded by three or 
more HUVEC cells84. The cell-free conditioned media from MCF7-miR526b and MCF7-
miR655 cell lines, initiated tube formation at the 8hr time-point and significantly stimulated 
the formation of both tubes and branch-points at the 24hr time-point when compared to the 
MCF7 control (Figure 2-6 B, C, D). 
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Figure 2-6: Cell-free conditioned media from MCF7-miR526b and MCF7-miR655 cell lines, 
promotes native tube formation of HUVECs in a time-dependent order. (A) Chart shows 
HUVEC tube formation in the basal and complete (negative and positive controls) HUVEC 
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media at 2 and 24-hr time points. (B)Tube formation assay at 24-hour time-point showed a 
higher number of tubes and branch points (shown by light blue circle and arrows, respectively) 
with treatment of MCF7-miR526b or MCF7-miR655 conditioned media than that of MCF7 
conditioned media. Tube formation assay was performed as a triplicate independent 
experiments and data are presented as mean ± SEM of tube number and branch points, per 
condition. (C and D) Quantification shows a significantly higher number of tubes and branch 
points in MCF-miR526b and MCF7-miR655 conditioned media than MCF7 conditioned 
media; * indicates p<0.05. 
2.6.4 COX2 Inhibitor (COX2-I) and EP4 Antagonist (EP4A) Inhibit miRNA induced 
HUVEC cell migration and tube formation 
PGE2 is an inflammation mediating ligand, produced by COX-2 enzyme activity. 
PGE2 binds to the primary receptor EP4 and this interaction results in the upregulation of 
phosphorylation of PI3K/Akt, activating pathways which lead to the promotion breast cancer 
metastasis72, 85.  To determine whether the miRNA-induced functions is due to the involvement 
of COX-2 activity or on EP4-signalling, we added COX-2 inhibitor (COX-2-I, NS398), EP4 
antagonist (EP4A, ONO-AE3-208), or PI3K/Akt pathway inhibitor (Wortmannin, WM), in 
addition to conditioned media from MCF7-miR526b, MCF7-miR655, or MCF7. The above 
conditions were observed at different time-points. The addition of COX-2-I reduced the 
miRNA-induced HUVEC migration and tube formation, while addition of either EP4A or WM 
resulted in complete inhibition of HUVEC migration (Figure 2-7 A,B,C,D) and tube formation 
capacities at 24-hr time-point (Figure 2-8 A,B,C,D). 
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Figure 2-7: COX2 inhibitor (COX2-I) and EP4 antagonist (EP4-A) abrogates miRNA-
conditioned media induced migration of HUVEC in a time-dependent manner. (A) Migration 
inhibition assay at 0, 4 and 8-hour time-point (B) Migration inhibition assay at 24-hour time-
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point, with the abrogation of miRNA induced HUVEC migration in the COX2-I and EP4-A 
conditions than the vehicle (3% DMSO). Higher wound size was observed in MCF7-miR526b 
/MCF7-miR655 conditions with COX2-I and EP4-A than the vehicle (from dark to light blue). 
(C and D) Quantification of the wound width showed a significant difference in the wound 
sizes from COX2-I/EP4-A conditions compare to the vehicle. Scratch-wound migration 
inhibition assays were conducted as three independent experiments and data presented as 
triplicate mean ± SEM. * and ** indicates P<0.05 & P<0.01 respectively. 
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Figure 2-8: COX2 inhibitor (COX2-I), EP4 antagonist (EP4-A) and PI3K/Akt inhibitor 
abrogates enhanced tube formation of HUVEC induced by conditioned media from MCF7-
miR526b and MCF7-miR655 cell lines, in a time-dependent order. (A) HUVEC tube formation 
with miRNA-high conditioned media and addition of COX2-I, EP4-A, and WM at 2 and 12-hr 
time-points. (B) HUVEC tube formation with miRNA-high conditioned media and addition of 
COX2-I, EP4-A, and WM at 24-hour time-point. Abrogation of complete HUVEC tube 
network was observed in the COX2-I, EP4-A and WM conditions compared to the vehicle (3% 
DMSO).  (C and D) Quantification showed a significantly higher number of tubes and branch 
points in the vehicle than the COX2-I/EP4-A/WM conditions. Tube formation inhibition assays 
were conducted as three independent experiments and data presented as triplicate mean ± SEM; 
*p<0.05, ** p<0.01. 
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2.7 Discussion 
Overexpression of VEGFs in the tumor microenvironment has been shown to 
contribute to cancer progression and metastasis, due to their roles in angiogenesis. The role of 
VEGF-A, VEGF-C and VEGF-D as key regulators of angiogenesis and lymphangiogenesis is 
well establsihed86. The growth of avascular tumor is limited by size (1-2mm), after which it 
essentially requires a blood vessel supply for oxygen and nutrients. Angiogenesis in cancers 
follows the same process as physiological angiogenesis, which includes proliferation, 
migration and differentiation of endothelial cells (EC) from already existing blood vessels. 
However, tumor-associated angiogenesis adopts a more complex process, provoked by poor 
oxygen conditions within the core of a growing tumor mass87. The hypoxic condition of a 
growing tumor activates the angiogenic switch which regulates the production of VEGFs. 
Many miRNAs have been shown to target and regulate VEGF signaling in angiogenesis. In 
this study, I show that overexpression of miR-526b and miR-655 in MCF7 breast cancer cell 
lines stimulates angiogenesis by the production and secretion of VEGFs into the tumor 
microenvironment.  
The specific roles of other miRNAs in tumor-associated angiogenesis are well documented in 
cancer. Cascio et al reported that oncogenic miR-20b regulates VEGF production in breast 
cancer cells by targeting hypoxia inducing factor (HIF)-1α88. The ectopic overexpression of 
VEGFs in tumor microenvironment have been found to associate with overexpression of 
miRNAs which are involved in angiogenesis. Luengo-Gil et al showed that miR-20a 
upregulation correlates with increased VEGF-A expression in tumor-associated 
angiogenesis89. However,  some miRNAs have also been reported to regulate both angiogenesis 
and lymphangiogenesis by inhibiting the expression of VEGF-A, VEGFR-2 and VEGR-3 in 
lung cancer83. In breast cancer-associated lymphangiogenesis, high expression of VEGF-C and 
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VEGF-D has been shown to signal along the COX-2 dependent PI3K/Akt axis90. Furthermore, 
Majumder et al has shown that miR526b and miR655 is upregulated by COX-2 overexpression 
via the PI3k/Akt/NFKB pathway63, 69 .  
We showed that overexpression of miR526b and miR655 in MCF7 cell lines results in the 
significant upregulation of vascular markers, VEGF-A, (angiogenesis); VEGF-C, VEGF-D 
(lymphangiogenesis).  Although, VEGFR1 & 2 are almost exclusively expressed on 
endothelial cells; both VEGFR-2 and VEGFR-3 have been shown to be functionally expressed 
on lung cancer cells91.  Moreover, VEGFR-2 involvement in the autocrine regulation of 
angiogenesis in breast cancer cell lines is well established92. We also showed that 
overexpression of miR-526b and miR-655 in MCF7 breast cancer cell line results in significant 
upregulation of VEGFR-1 at the mRNA level. Data also showed marginal increase in the 
mRNA expression of VEGFR-2 (Figure 2-4). The above results suggest that the upregulation 
of VEGF-A, VEGF-C, and VEGF-D in MCF7-miR526b and MCF7-miR655 results in the 
production and release of these ligands into the tumor microenvironment, which may feed into 
an autocrine loop on breast cancer cells for VEGFR1 activation. This indicates a possible role 
of miR526b and miR-655 in VEGF-VEGFR autocrine regulation of breast tumor-associated 
angiogenesis93. Furthermore, the significant mRNA upregulation of COX-2, VEGF-A, VEGF-
C, and VEGF-D, and the main PGE2 receptor, EP4 in MCF7-miR526b and MCF7-miR655 
cell lines suggest that both miRNAs promote the release of both VEGFs and PGE2 into the 
tumor microenvironment to regulate the autocrine signaling of angiogenesis via the VEGFR 
and EP4 receptor in breast cancer82. A thousand fold increases in VEGFR mRNA expression 
require further validation at the protein level.  
In another report, Kohlhapp et al showed that dysregulated miRNA expressions in cancers is 
associated with the molecular cross-talk between the tumor cells and the stromal cells. They 
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further show that the co-culture of endothelial cells and brain cancer cells upregulate miR-296 
via VEGF and EGF signaling. This was observed to promote endothelial cell migration and 
tube formation94. Adapting the same principle as above, I investigated the paracrine effect of 
cell-free supernatant from MCF7-miR526b and MCF7-miR655 cell lines on HUVEC. 
Functional assays using scratch-wound healing migration assays and tube formation assay on 
GFR Matrigel were conducted to test the capacity of both miRNAs to promote these HUVEC 
functions. Here, I show that the cell-free supernatant collected from MCF7-miR526b and 
MCF7-miR655 overexpressing breast cancer cell lines promotes both migration and tube 
formation of HUVEC cells in vitro. In both assays, migration was initiated at the 4h time-point, 
showing an earlier alignment of the HUVECs to form branch-points before tube formation, 
which started at the 8h time-point. About three or more HUVEC cells were observed 
connecting with themselves to form complete tubes. Quantification of the wound size and tube 
number in HUVEC migration and tube formation assays, show that both miRNA-high 
conditioned media significantly promote HUVEC migration and tube formation at the 24h 
time-point (Figure 2-5 and 2-6).  
Moreover, we found VEGFR-1 and VEGFR-2 to be upregulated in HUVEC cells following 
treatment with conditioned media from miRNA overexpressing cells. Also, the expression of 
EP4 receptor was found to be upregulated in HUVECs treated with conditioned media from 
miRNA high cell lines (Figure 2-4). Here, we propose that overexpression of miR-526b and 
miR-655, promote the secretion of vascular growth factors, VEGF-A, VEGF-C and VEGF-D, 
to induce migration and tube formation of HUVEC. This indicates that miR526b and miR655 
might be involved in promoting tumor-associated angiogenesis as well as lymphangiogenesis 
in breast cancer, since VEGFs production in the tumor microenvironment have been 
established as major mediators of endothelial cell migration and lymphangiogenic activity95. 
Specifically, VEGF-A, is the principal mediator of proangiogenic activity and migration of 
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endothelial cells lining blood vessels. VEGF-A binds with both VEGFR-1 and VEGFR-2, to 
activate a multiple downstream cell signaling pathways, resulting in the promotion of 
endothelial cell proliferation, migration and angiogenesis75. 
Recently, we have shown that PGE2 promotes embryonic vascular maturation and 
angiogenesis in vertebrates by upregulating Vegf-a ligand and its cognate receptor, Vegfr-2 in 
Zebrafish embryos96. Majumder et al have reported that the overexpression of COX-2 in 
genetically variable breast cancer cell lines resulted in the upregulation of both oncogenic 
miRNA and overproduction of PGE2 in human breast cancer63, 70. They measured PGE2 in 
COX-2 overexpressing cell secretions and reported that secretory PGE2 in the breast tumor 
microenvironment binds to G-protein-coupled receptor, EP4, to stimulate paracrine and 
autocrine regulation of lymphangiogenesis through the non-canonical PI3K/Akt and ERK 
pathways85. In another murine breast cancer model, Majumder et al showed that, VEGF-C and 
VEGF-D production by COX-2/PGE2 high cells induced lymphangiogenesis, through the 
PI3K/Akt/ERK axis90. However, stable overexpression of miR526b and miR655 in poorly 
metastatic breast cancer cell lines promotes migration and invasion, epithelial-to-mesenchymal 
transition and metastasis through the COX-2/PGE2/EP4/PI3K/Akt axis63, 70. Here, I 
investigated the involvement of the COX-2/EP4/PI3K/Akt pathway in miR526b and miR655 
induced angiogenesis. 
To test the involvement of the above pathway in miRNA-mediated HUVEC functions, I used 
COX2-I, EP4A or PI3K/Akt inhibitor along with miRNA-high cell conditioned media to test 
both HUVEC migration and tube formation. Here, EP4A could significantly abrogate HUVEC 
tube network, however, PI3K/Akt inhibitor was able to completely block these phenotypes 
(Figure 2-7 and 2-8). This suggests that miR-526b and miR-655 induce angiogenesis via EP4 
and PI3K/AkT pathways. Nevertheless, the exact mechanisms by which miR-526b and miR-
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655 stimulate angiogenesis in breast cancer are not known yet. In 2015, Majumder et al have 
reported that PTEN (phosphatase and tensin homolog), is downregulated in COX-2 
overexpressing MCF7 cell lines. PTEN is a tumor suppressor gene and a common target of 
miR-526b and miR-65563, 70. In a different study, Liu et al reported that miR-21 targets PTEN 
to stimulate Akt/ERK downstream signaling, which increases the expression of HIF1α and 
VEGF. PTEN is thought to act as a tumor suppressor gene by inhibiting the PI3K/Akt pathway 
and HIF-1α. The effect of HIF-1α in angiogenesis-associated cell signaling turns on the 
transcription of VEGFs97, 98. We propose that both miR-526b and miR-655 target this pathway, 
resulting in the loss of control of HIF1α and over-production of VEGF in the tumor 
microenvironment. Thus, both miRNAs promote the production of VEGF in the tumor milieu, 
which facilitate tumor-associated angiogenesis in breast cancer.  
I did not measure and correlate the angiogenesis and lymphangiogenesis markers expression 
and with miRNA expression using human breast cancer samples. However, we have collected 
human benign and malignant samples to complete the above experiments. Presently, 
investigation is ongoing in our laboratory to find the translational link between angiogenesis 
regulation and both miRNA in human breast cancer. This will further establish these two 
miRNAs as breast cancer modulators and as biomarkers. 
2.8 Conclusion 
In summary, the results of this study establish a new role of oncogenic miR-526b and 
miR-655 in breast cancer angiogenesis. This is vital in establishing the involvement of miRNAs 
in breast cancer metastasis due to their roles in tumor-associated angiogenesis. The proposed 
schematic pathway is presented as Figure 2-9. 
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Figure 2-9: Figure shows the proposed pathway of miR-526b and miR655-induced 
angiogenesis via PTEN inhibition. The suppression of HIF-1α and the PI3K/Akt pathway is 
aborted by the upregulation of these two miRNAs. Without regulation, transcription factor 
HIF1α promotes VEGF transcription, leading to an overproduction of VEGFs and subsequent 
release into the tumor microenvironment. VEGF-A molecules specifically binds VEGFR-1&2 
receptors present on vascular endothelial cells (VEC), to promote angiogenesis. Similarly. 
VEGF-C&D binds to VEGFR-2&3 to promote lymphangiogenesis. The suppression of the 
negative regulation of PI3k/Akt pathway by PTEN, promotes growth and proliferation of blood 
vessels.  
 
 
 
 
42 
 
CHAPTER 3 
Testing the potential of miR526b and miR655 as Breast Cancer Biomarker 
3.1 Background 
Breast cancer (BC) is the most commonly diagnosed cancer among women. It 
contributes about 25% of all new cancer cases and 15% of cancer-related deaths worldwide. A 
total of 1.7 million women develop this disease each year and 30-40% of them are under 40 
years of age99, 100. Mortality rates due to breast cancer have declined in recent times due to 
improvements in early diagnosis and treatment101. About 98% of women diagnosed of the 
disease at early stages of tumor recover completely. In contrast, only 23% of women diagnosed 
with metastatic breast cancer survive from the disease102. An improved survival from BC 
requires the development of sensitive biomarkers that could detect tumors at earliest stages and 
differentiate them at late stages. Mammography is currently used as a gold standard for BC 
screening and has contributed to reducing the disease mortality. However, the difficulty of 
detecting tumors in dense breasts and false positive results of mammograms are huge 
limitations. Other classical methods of cancer detection such as ultrasound, are not tissue-
specific. Hence, they are less useful for diagnosis and treatment of the disease103. Traditional 
tumor markers such as carcinoembryonic antigen (CEA) and carbohydrate antigen 15-3 (CA 
15-3) are clinically used as prognostic biomarkers but have low sensitivity and specificity104. 
Hence, breast cancer patients require a minimally invasive, sensitive and tumor-specific 
biomarkers for early detection of the disease. Recently, micro RNAs have been identified as 
stable molecules in body fluids, with the potential for accurate detection and predictions of 
cancers105.  
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3.2 MicroRNA as a Blood Biomarker 
MicroRNAs (miRNA, miR) are endogenously produced non-coding small RNA 
molecules that regulate gene expressions at post-transcriptional level. miRNAs are secreted by 
both tumor and stromal (normal) cells into the interstitial fluid, to form the fluid part of tumor 
microenvironment106. Circulating miRNA in body fluids show aberrant expressions in tumors 
than normal breast tissues107. Previous studies show that differential expressions of circulating 
miRNAs can distinguish different stages of growing tumors108. Moreover, circulating miRNA 
can be quantified by qRT-PCR in blood plasma109. In breast cancer, qRT-PCR quantification 
of systemic miR-195 shows that circulating miRNA increases with tumor growth. However, 
no research has shown the clinical value of plasma pri-miRNA expression in human breast 
cancer.   
MicroRNA-526b and miR-655 are small RNA molecules that have been well studied in breast 
cancer. Different oncogenic roles of miR526b and miR655 have been well studied in 
genetically variant cell lines of human breast cancer. Accumulating evidences show that 
miR526b and miR655 expressions are high in the tumor and correlates with poor patient 
outcome 44, 110. However, the biomarker potential of pri-miR526b and pri-miR655 in plasma 
of breast cancer patients have never been tested before now. In this study, we hypothesized that 
oncogenic miR526b and miR655 are detectable in the blood plasma of breast cancer patients. 
Here, we quantified and compared the miRNA and pri-miRNA expressions in the plasma of 
breast cancer patients and benign subjects. Within the scope of our knowledge, this study is 
among the first few RT-PCR validated studies that compares tumor-specific circulating 
miRNA expressions with their Pri-miRNAs in breast cancer. We show for the first time that 
pri-miR526b and pri-miR655 are upregulated in the plasma of breast cancer patients compared 
to individuals with no evidence of disease. Both pri-miRNAs have approximately the same 
levels of expressions with their mature miRNAs (miR526b and miR655) in the patient plasma. 
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Furthermore, both pri-miRNAs showed increased expression in plasma of tumor stage 1 breast 
cancer patients and could differentiate early and late tumor stages. 
3.3 Aim 
To show the biomarker potential of pri-miR526b and pri-miR655 expression in the 
blood plasma of breast cancer patients. 
3.4 Materials and Method 
3.4.1 Ethical Approval of the Study 
Human plasma and matched tissue samples from the human breast cancer patients and 
subjects with no evidence of disease (control) were obtained from the London Regional Cancer 
Program, Ontario. These samples were collected based on the ethics approval to Dr. Muriel 
Brackstone, an Oncology Surgeon at London Regional Cancer Program and prof. Peeyush K 
Lala at University of Western Ontario. Blood samples were collected from diagnosed breast 
cancer patients undergoing chemotherapy, radiotherapy and surgery with their consent. These 
samples were processed and separated into plasma within 10-30 minutes. All samples were 
aliquoted into 2ml cryo vials and preserved at -80°C for storage. We received these samples 
through our collaboration with the London Regional Cancer Program, Ontario and University 
of Western Ontario. All plasma and tissue samples were transferred to Dr. Majumder at 
Brandon University following Material Transfer Agreement and the project was ethically 
approved by Brandon University Ethical Approval Committee (#21986).  
3.4.2 Study Design 
A total of 90 breast cancer and 20 disease-free (control) plasma samples with matched-
tumor biopsy tissues were used for this study. This study is divided into two major steps: 
miRNA marker selection and pri-miRNA marker validation. Marker selection was done by 
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comparing the level of expression of miRNAs with pri-miRNAs in 5 plasma and matched 
tumor samples from breast cancer patients. Both pri-miRNA expressions in 90 breast cancer 
and 20 control plasma samples were validated with relative RT-PCR quantification by 
normalizing them to RPL5.  
3.4.3 Sample Preparation and RNA Extraction from Plasma samples 
Total RNA was extracted from 350µl of blood plasma using Qiagen® miRNeasy Mini 
and further processed to enrich miRNA using miRNeasy Mini Cleanup columns (Qiagen, ON). 
Denaturation and phase separation were done using Qiazol® (Qiagen, ON) according to 
manufacturer’s protocol with little modification. The resulting clear aqueous phase was 
pipetted into a fresh 2ml microcentrifuge tube, vortexed with 1.5ml volumes of 100% ethanol 
and applied to miRNeasy Mini columns (Qiagen, ON). The spin columns were further washed 
with RWT and RPE buffers according to the manufacturer’s protocol. The purified RNA and 
miRNA were eluted with 20µl of RNase-free water at 10000rpm for 1 minute.  
3.4.4 RNA Extraction from Tumor samples 
Frozen tumor biopsy samples from breast cancer patients and non-malignant tissues 
from individuals with no evidence of disease were lysed with 700µl Qiazol® lysis reagent and 
homogenized by vortexing. Total RNA was isolated using Qiagen® miRNeasy Mini and 
miRNeasy Mini Cleanup columns (Qiagen, ON) as described for plasma samples above.  
3.4.5 Complementary DNA Synthesis 
Reverse transcription was performed using TaqMan® RNA Reverse Transcription Kit 
(Applied Biosystems, USA) and highly efficient random primers for pri-miR526b and pri-
miR655 quantification. A standard amount of 2µg of RNA was transcribed using the 
Multiscribe Reverse Transcriptase enzyme (50U/µl, Applied Biosystems, USA) in a 20µl 
reaction volume. Every batch of cDNA synthesis was accompanied by reversely transcribed 
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negative control, lacking RNA (RT blank). Each reaction master mix consists of 4.2µl Rnase-
free water, 2µl 10X RT buffer, 0.8µl dNTPs (100mM), 2µl 10X random primers, 1µl 
Multiscribe Reverse Transcriptase, and a fixed RNA sample. 
Similarly, TaqMan® miRNA Reverse transcription was performed using TaqMan® miRNA 
Reverse Transcription Kit (Applied Biosystems, USA) and miRNA-specific RT primers for 
miR526b and miR655 quantification.  Each reaction master mix consist of 4.2µl Rnase-free 
water, 2µl 10X RT buffer, 0.8µl dNTPs (100mM), 2µl 5X miRNA-specific primers, 1µl 
Multiscribe Reverse Transcriptase, and a fixed volume of enriched miRNA sample. 
3.4.6 Real-time Quantitative PCR 
For all samples, TaqMan real-time PCR reactions were performed in a 20µl reaction 
volume consisting of 10µl TaqMan® Universal PCR Master Mix with no AmpErase UNG 
(Applied Biosystems, USA), 1µl of 20X pri-miRNA/miRNA-specific primer/probe mix 
(Applied Biosystems, USA), 1µl of cDNA template and made up to 20µl reaction volume with 
Rnase-free water. A 0.2µl of the cDNA was used for the tumor RNA/miRNA quantification 
and made up with Rnase-free water. Real-time PCR was carried out on Research Corbett® 
cycling machine under the following conditions: initial hold of 95°C for 10minutes, then 
50cycles of 95°C for 10seconds, 60°C for 60 seconds, 72°C for 60seconds and a hold at 4°C. 
Both miRNA and pri-miRNA expressions were normalized to RNU44 and RPL5 respectively. 
3.4.7 Data Analysis 
The quantitative real-time PCR (qRT-PCR) data of miRNA and pri-miRNA 
expressions were analyzed using the relative quantification method and all data were 
normalized to the expression of the reference genes, RNU44 and RPL5 respectively. For all 
patient specimens, only duplicate run for each probe was performed, because we had limited 
sample volume. However, 5% of the samples were repeated to confirm consistency of the cycle 
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threshold (Ct) values. The expressions of the miRNA/pri-miRNA in each sample were 
normalized by subtracting the Ct value of the endogenous control/reference gene from the Ct 
value of target gene. This relative change in expression is referred to as delta Ct (∆Ct) and was 
used to compare the individual differences in pri-miRNA expressions. Here, a more negative 
ΔCt indicates more expression of miRNA/pri-miRNA111.  
ΔCt = Average Ct miRNA or pri-miRNA – Average Ct of Endogenous Control 
Diagnostic value of pri-miRNA was performed using MedCalc statistical software (v18.2.1) 
and online Z-score calculator. Statistical significance was tested at p < 0.05. 
3.5 Result 
3.5.1 Clinicopathological Characteristics of Breast Cancer Patients  
The human blood plasma and matched tumor samples used in this study were collected 
from female breast cancer patients receiving radiation with adjuvant chemo and/or hormonal 
therapy at London Regional Cancer Program, Ontario, Canada. The breast cancer patients 
(malignant subject, n = 90) and individuals with no evidence of disease (control, n = 20), were 
distributed according to their age groups. The ages of breast cancer patients and benign ranges 
from 42-91 (averaging 64) and 52-87 (averaging 66) years respectively. There were no 
statistical differences of age between the breast cancer and control subjects (P > 0.05). The 
clinical and pathological details of the breast cancer subjects were grouped as breast cancer 
subtypes based on the estrogen-progesterone- HER2 status and their tumor stages respectively 
(Table 3-1).  
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3.5.2 Expression of miRNA and Pri-miRNA in Breast Cancer Plasma and Tumor 
Owing to the availability of small volumes of patient plasma and the requirement of 
high volumes of miRNA to make miRNA-specific cDNA, we needed to standardize a 
procedure that can use minimum patient sample and give maximum output. So, we measured 
the expressions of both target miRNA (normalized to RNU44) and pri-miRNA (normalized to 
RPL5) in 5 randomly selected breast cancer patient plasma with matched biopsy samples. 
TaqMan qRT-PCR assay was conducted in duplicates for each sample. Data showed that both 
mature miRNAs, miR526b and miR655 with their pri-miRNAs, pri-miR526b and pri-miR655 
are expressed in the plasma and tumor of the breast cancer patients. To test the level of 
expression of miRNA and the pri-miRNA in breast cancer samples, a pairwise analysis of 
Table 3-1 The Demographic Distribution of Breast Cancer Patients and Benign Control   
Subjects  Control 
N= 20 (%) 
Breast Cancer 
N= 90 (%) 
Sex Male 0 0 
Female 20 (100) 90 (100) 
Age distribution (years) Range 52-87 42-91 
Age (years) Mean  SD 66  11 64  12 
ER status Positive n/a 80 (88.80) 
Negative n/a 10 (11.10) 
PR status Positive n/a 75 (83.30) 
Negative n/a 15 (16.60) 
HER2 status Positive n/a 19 (21.10) 
Negative n/a 71 (78.80) 
EP PR HER2 status Negative n/a 8 (8.80) 
 
 
Tumor-Nodal-Metastasis 
Status 
Stage 1 n/a 
44 (48.80) 
Stage 2 n/a 
37 (41.10) 
Stage 3 & 4 n/a 
9 (10.0) 
49 
 
normalized expressions of miRNA and pri-miRNA expressions was conducted. While miR655 
showed no difference in the level of expression in the tumor and plasma samples; it is different 
for miR526b (Figure 3-1A). Most interestingly there is no statistical difference in normalized 
expressions of both miRNA and Pri-miRNA expression in plasma samples (Figure 3-1B). 
                        
                         
Figure 3-1: Shows the pairwise analysis of normalized expressions of miRNA and pri-miRNA 
in breast cancer patient plasma and tumor. (A) Chart shows the normalized expressions of 
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miRNA (Mean ± SEM: miR526b, 7.64 ± 0.61 and miR655, -2.71 ± 1.75) and pri-miRNA 
(Mean ± SEM: pri-miR526b, 2.46 ±1.70 and pri-miR655, -1.01 ± 1.33) in 5 pilot breast cancer 
tumor samples. Quantification of miR655 and pri-miR655 in the tumor samples, showed no 
significant difference (P = 0.46) in expression. However, pri-miR526b expression was higher 
significantly (P = 0.02) in the tumor samples. (B) Chart shows the normalized expressions of 
the miR526b and pri-miR526b (Mean ± SEM: miR526b, -2.77 ± 2.26 and pri-miR526b, -1.94 
± 1.80; P = 0.78) with that of miR655 and pri-miR655 (Mean ± SEM: miR655, -2.52 ± 5.04 
and pri-miR655, -3.28 ± 1.27; P = 0.88) in the same patient-matched plasma samples. 
Generally, Unpaired t-test comparing the mean of miRNAs and pri-miRNAs in plasma showed 
no statistical difference in expression. The miRNA and pri-miRNA expressions were 
normalized to RNU44 and RPL5 expressions respectively. The horizontal line shows the 
median of data with a mark for the mean of distribution while the vertical lines show the 
minimum and maximum data. 
3.5.3 Expression of Endogenous Control gene RPL5 in Control and BC Patient plasma 
Before qRT-PCR validation of pri-miRNA expression in plasma of breast cancer 
patients, TaqMan qRT-PCR assay was conducted in plasma samples (n=15). Here, we analyzed 
the stability of the endogenous control gene, ribosomal protein L5 (RPL5) in both benign 
(control) and breast cancer patient plasma. RPL5 was expressed in all benign (Ct range 32.63 
– 35.94) and malignant plasma samples (Ct range 32.24 – 36.46) with an average Ct value of 
34.11 and 33.80 respectively. We compared the mean Ct values of RPL5 in plasma, using 
GraphPad Prism software version 5 (GraphPad Software, CA, USA). Figure 3-2 result showed 
that variations in RPL5 expressions in both breast cancer and the control plasma samples is not 
statistically significant (P = 0.43). So RPL5 is an ideal control gene to test experimental markers 
expression in control and tumor samples. 
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Figure 3-2: Chart shows a scatter diagram of average Ct values of RPL5 from a randomized 
control (n =15) and breast cancer (n =15) patient plasma. Following a qRT-PCR analysis 
conducted in duplicates, RPL5 expression was observed in control (Ct range: 32.63 – 35.94) 
and breast cancer (Ct range: 32.24 – 36.46) plasma samples. An unpaired t-test conducted on 
the average Ct of control and tumor samples showed a p-value of 0.43.  
3.5.4 Expression of Pri-miR526b and Pri-miR655 in Plasma of Benign and BC Patients 
Following the extraction of total RNA and cDNA synthesis of RNA from benign (n 
=20) and breast cancer (n =90) plasma samples, qRT- PCR assay was conducted in duplicates 
to quantify pri-miR526b and Pri-miR655 expressions. The pri-miRNA expression was 
normalized to endogenous gene, RPL5. Normalized expression of pri-miR526b was observed 
to be significantly higher in breast cancer (Mean ± SEM, 1.24 ± 0.45) when compared to the 
benign control (Mean ± SEM, 6.13 ± 0.84), with a p-value of 0.0001. Similarly, normalized 
expression of pri-miR655 was significantly increased in breast cancer plasma (Mean ± SEM, -
0.85 ± 0.38) compared with benign (Mean ± SEM, 0.79 ± 0.11), with a p-value of 0.0475 
(Figure 3-3). 
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Figure 3-3: qRT-PCR analysis of normalized expression of pri-miR526b and pri-miR655 in 
benign and breast cancer patient plasma (A) Chart shows pri-miR526b expression was 
significantly increased in breast cancer patient plasma (Mean ± SEM, 1.24 ± 0.45) when 
compared with the benign (Mean ± SEM, 6.13 ± 0.84), with a p-value of 0.0001 using graph 
pad t-test. (B) Chart shows normalized expression of pri-miR655 in plasma was significantly 
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higher in breast cancer (Mean ± SEM, -0.85 ± 0.38) when compared with the benign (Mean ± 
SEM, 0.79 ± 0.11), with a p-value of 0.0475 using graph pad t-test. All data were normalized 
to the endogenous control, RPL5. The horizontal line shows the median of data with a mark 
for the mean of distribution while the vertical lines show the minimum and maximum data. * 
& ** indicates P < 0.05 and P < 0.001 respectively. 
3.5.5 Expression of Pri-miRNA in Plasma Differentiates BC Tumor Stage 1 from Benign 
 We assessed the usefulness of highly expressed pri-miR526b and pri-miR655 in 
plasma, for early detection of breast cancer. Here, we further analyzed the normalized 
expression of pri-miR526b and pri-miR655 in the plasma of breast cancer patients with the 
earliest tumor stage (stage 1). Normalized expression of both pri-miRNA showed a 
significantly higher expression in breast cancer plasma (Mean ± SEM: pri-526b, 1.33 ± 0.63 
and pri-miR655, -1.33 ± 0.63) compared to the benign. An unpaired t-test comparing 
normalized expression of pri-miR526b and pri-miR655 in benign (n = 20) and tumor stage 1 
breast cancer plasma (n = 44), showed a significantly increased pri-miRNA expression, with 
p-values of 0.0001 and 0.0123 respectively (Figure 3-4). This signifies that both pri-miRNAs 
can be used as early tumor stage screening markers. 
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 Figure 3-4: qRT-PCR analysis showing normalized pri-miR526b and pri-miR655 expression 
in the plasma of benign and tumor stage 1 breast cancer. (A) Chart shows normalized pri-
miR526b expression is significantly increased in tumor stage 1 breast cancer (n = 44; Mean ± 
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SEM, 1.33 ± 0.63; p = 0.0001) compared to benign. (B) Chart shows normalized pri-miR655 
expression is significantly increased in tumor stage 1 patients (n = 44; Mean ± SEM, -1.33 ± 
0.63; p = 0.0123 compared to benign. All data were normalized to the endogenous control, 
RPL5. The horizontal line shows the median of data with a mark for the mean of distribution 
while the vertical lines show the minimum and maximum data. * & ** indicates P < 0.05 and 
P < 0.001 respectively. 
3.5.6 Pri-miRNA expression in Plasma is correlated with Progressive Tumor Stages 
To associate pri-miR526b and pri-miR655 expressions in breast cancer patient plasma 
with tumor progression, 90 malignant plasma samples were sorted according to their tumor 
stages, 1, 2, 3 & 4. Few samples of tumor stages 3 and 4 were combined as one cohort for 
statistical analysis. Differential expression of both pri-miRNAs was tested with 2-sample T-
test by comparing tumor stage 1 pri-miRNA expression with each progressive tumor stage. 
Interestingly, pairwise T-test analysis comparing the average normalized pri-miRNA 
expressions of early tumor stage (stage 1) patients and the late tumor stages (stage 3&4). 
Results showed a significantly increase expression in the later tumor stages compared to the 
tumor stage 1, with p-values of 0.009 and 0.04 respectively (Figure 3-5). So, miRNA 
expression can distinguish early and late stages of tumors. 
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Figure 3-5: qRT-PCR data of normalized pri-526b and pri-miR655 expressions in BC patient 
plasma. (A) Chart shows the normalized expressions of pri-miR526b in plasma of BC patients 
of tumor stage 1-4 (Mean ± SEM: stage1, 1.33 ± 0.63; stage2, 0.84 ± 0.70; stages 3&4, -1.37 
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± 2.19). (B) Chart shows the normalized expressions of pri-miR655 in plasma of BC patients 
of different tumor stages (Mean ± SEM: stage1, -1.33 ± 0.55; stage2, -0.64 ± 0.69; stages 3&4, 
-3.06 ± 0.62). Comparing the mean of normalized expressions of pri-miR526b and pri-miR655 
in plasma of tumor stage 1 with later tumor stage (stage 3 & 4) using a graph pad t-test, a 
significant difference in expression was observed (p-value = 0.009 and 0.04 respectively). The 
horizontal line shows the median of data with a mark for the mean of distribution while the 
vertical lines show the minimum and maximum data. * & ** indicates P < 0.05 and P < 0.01 
respectively. 
3.5.7 Relevance of Pri-miRNA as a Biomarker 
 To further evaluate the diagnostic value of pri-miR526b and pri-miR655 at the 
clinic, we conducted a diagnostic test using Medcalc software to test the Sensitivity and 
Specificity of both pri-miRNA as a biomarker. With a cut-off mark of 0.00 ΔCt value (no 
difference in pri-miRNA expression between case and control) and high pri-miRNA expression 
as – ΔCt value, we observed high percentage of pri-miRNA expressions in the plasma of BC 
patients at early and late tumor stages (Table 3-2A). I calculated both false positive rate (FPR) 
and false negative rate (FNR) of both pri-miRNA to show their effectiveness in detecting true 
disease situations. Results show that pri-miR655 expressions in the plasma, have a lower false 
negative rate (13%) than pri-miR526b, which indicates a higher sensitivity (86.89%) to 
detecting breast cancer (Table 3-2B). Results showing both miRNAs are highly specific and 
can predict disease with 81% accuracy. 
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Table 3-2A    Tumor Stages and high pri-miRNA Expression in Plasma of  
Breast Cancer Patients 
 
Tumor Stages 
I 
II 
III & IV 
 
N (%) 
miR-526b high 
N (%) 
miR-655 high 
N (%) 
44 (43.8) 19 (43.2) 25 (56.8) 
37 (41.1) 13 (35.1) 20 (54.1) 
9 (10.0) 6 (66.7) 8 (88.9) 
 
3.5.7 Distribution of Pri-miRNA expression in various hormonal receptor status    
stratified tumor samples 
 We further conducted Z-score analysis to show whether plasma expression levels 
of both pri-miRNA are clinically useful for different hormonal subtypes in breast cancer. So, 
we calculated the proportions of high pri-miRNA expression according to estrogen receptor 
(ER), progesterone receptor (PR) and human epidermal receptor status of the patients (Table 
3-3A). Data showed a significantly higher proportion of pri-miRNA high expressing samples 
for the ER-ve, and PR-ve than the positive hormonal status, with a p < 0.01(Table 3-3B). So, 
these miRNAs can distinguish ER and PR negative samples very significantly. 
 
 
Table 3-2B   Diagnostic Relevance of pri-miR526b and pri-miR655 in Breast Cancer 
                         
Cut-off 
Sensitivity 
(%) 
Specificity 
(%) 
FPR 
(%) 
FNR 
(%) 
Accuracy 
(%) 
Pri-miR526b high 0.00 67.86 96.30 3.00 32.14 81.82 
Pri-miR655 high 0.00 86.89 75.51 24.49 13.11 81.82 
Table 3-3A     High pri-miRNA Expression in Plasma and ER-PR-HER2 Receptor 
Status of Breast Cancer Patients 
 
Receptor Status 
 
N (%) 
Pri-miR526b high 
N (%) 
Pri-miR655 high 
N (%) 
ER Status Positive 80 (88.8) 24 (30.0) 41 (51.3) 
Negative 10 (11.1) 7 (70.0) 10 (100) 
PR Status Positive 75 (83.3) 23 (30.6) 39 (52.0) 
Negative 15 (16.6) 8 (53.3) 14 (93.3) 
HER-2 Positive 19 (21.1) 4 (21.0) 11 (57.9) 
 Negative 71 (78.8) 25 (35.2) 36 (50.7) 
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3.6 Discussion 
Breast cancer is the most prevalent organ-specific cancer affecting women worldwide. 
Mammographic breast screening is currently the gold standard for early breast cancer 
examination. Mammography contributes high dosage of harmful radiations to breast cancer 
patients and excludes the younger women below the age of 50 years from clinical breast 
screening. Furthermore, mammogram contributes 9% of false positive results in all breast 
cancer diagnosis112. Research has shown that early detection of breast cancer correlate with 
high rate of patient survival113. This underscores the importance of identifying a minimally 
invasive biomarker with early detection potential. 
Presently, there is no specific blood-based biomarker for early diagnosis of breast cancer 
patients of different tumor status. Circulating miRNAs have emerged as novel biological 
molecules with high sensitivity of disease prognosis105. Hence, the quantification of circulating 
miRNA in the blood holds promise for a more reliable and sensitive test used for early diagnosis 
of cancer. In this study, we tested the potential of circulating plasma pri-miR526b and pri-
miR655 to serve as a breast cancer biomarker at the clinic. Here, we measured the normalized 
expressions of both miRNA and pri-miRNA in the plasma of breast cancer patients and benign 
individuals. Most convincingly, miRNA expression in plasma is very comparable to tissue 
miRNA expression. 
About half of breast cancer patients overexpress COX-2. Previously, we showed that COX-2 
overexpression upregulates oncogenic miR-655 and miR-526b in human breast cancer. We 
Table 3-3B       Z-Score Analysis of high pri-miRNA in Human Breast Cancer 
 according to ER-PR-HER2 Status 
                                             ER Status PR Status HER-2 Status 
 Z P Z P Z P 
High pri-miR526b -2.5097 0.01208 -3.1807 0.00148 -1.173 0.242 
High pri-miR655 -2.9331 0.00338 -2.97 0.00298 0.5573 0.57548 
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have established that both oncogenic miRNAs, promote all aggressive breast cancer 
phenotypes via EP4/PI3K/AkT signaling53. Both oncogenic miR526b and miR655 are 
significantly high in the tumor and correlate with poor patient survival54, 55. However, miRNAs 
are secreted as exosomes into the interstitial fluid and have been found to be very stable in the 
blood plasma114, 106, 115. Hence, the study of oncogenic miRNAs and their relationship with the 
progressing tumors is important for diagnostic purposes.  
We standardized plasma miRNA extraction procedure with a starting volume of 350µl, adapted 
from Qiagen purification protocol for miRNA116. We observed that 350µl of breast cancer 
patient blood plasma yielded at least 50ng of the miRNA, which showed a good expression of 
miR526b and miR655 on qRT-PCR. However, highly specific cDNA reverse transcription kit 
requires only 10µl of miRNA for cDNA synthesis. Due to the demand of high volume of 
miRNA, to make miRNA-specific cDNA, we quantified normalized expression of our target 
miRNA and the pri-miRNA in a few pilot plasma samples. Our data showed no significant 
difference in the plasma expressions of both mature miRNAs (miR526b and miR655) and the 
pri-miRNAs (pri-miR526b and pri-miR655) normalized to RNU44 and RPL5 respectively. 
This validation reduces the demand of more patient specimens (plasma or tumor) for the 
quantification of both miRNAs. This shows that we can synthesis cDNA using random primers 
and have a stock of cDNA for many other experimental disease-related probe screenings. 
Before validating the normalized expressions of our target pri-miRNAs in plasma, we tested 
the stability of the endogenous control gene, RPL5. We observed a stable expression of RPL5 
in both the benign and breast cancer plasma samples.  This result validated the correct selection 
of control gene55. The normalized expressions of pri-miR526b and pri-miR655 in plasma was 
significantly increased in breast cancer compared to the control. We further compared the level 
of normalized expressions of both pri-miRNAs in the plasma samples of tumor stage 1 patients 
with the control. qRT-PCR data showed that both pri-miR526b and pri-miR655 showed a 
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significantly increased expression in plasma of tumor stage 1 patients compared to benign. This 
observation is supported by Pigati et al which showed that miRNAs are selectively released 
into the circulating body fluids by both normal and malignant epithelial breast cells108. 
Furthermore, Heneghan et al showed that systemic plasma miRNA is increased in breast cancer 
patients at different tumor stages117.  
To test the differential expressions of pri-miR526b and pri-mi655 in plasma with tumor 
progression, we sorted the normalized expressions of both pri-miR526b and pri-miR655 in 
plasma of different tumor stages of breast cancer. Here, we observed pri-miR526b and pri-
miR655 in plasma showed no significant variation with tumor progression. However, this could 
be due to fewer sample distribution of stage 3 and 4 tumor samples. Nevertheless, a pairwise 
analysis of pri-miRNA expression in plasma of tumor stage 1 and other tumor stages, 
distinguished the early and late tumor stages in breast cancer. This strongly suggests that both 
miRNAs can be used as early diagnostic tumor marker. 
 Testing the diagnostic value of pri-miRNA at the clinic, we observed that pri-miR655 
has a much lower false negative rate FNR (13%) in expression than pri-miR526b. This is 
reflected in an optimum sensitivity score of 86.89% for pri-miR655, showing that while both 
miRNAs can be used as biomarker, miR655 is more sensitive in detecting breast cancer than 
miR526b. Moreover, Z-score analysis of high pri-miRNA expressing plasma samples showed 
a differential proportion of high pri-miRNA expression in ER and PR negative samples than 
the positives. So, the distribution of high-pri-miR526b and pri-miR655 in plasma of ER 
negative and PR negative patients, shows their usefulness in monitoring the treatment progress 
of this subclass of breast cancer, as shown in another study.118 We observed no difference in 
the proportion of high pri-miRNA expression between HER2 positive and negative status. This 
result could be due to the high number of HER-2 negative samples in the total sample 
distribution.  
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While we could distinguish tumors from control as early as stage 1 (small tumor), this study is 
limited by few samples in stage 3 and 4. To determine a threshold of miRNA expression that 
can distinguish or classify breast cancer according to tumor stages in plasma, we need more 
samples in the progressive stages.  Also, we have shown previously that COX-2 and EP4 
expression is highly correlated with miR526b and miR655 expression in human breast tumor54, 
55. The establishment of these miRNA expressions with COX-2 and EP4 expression in blood 
plasma would most likely be interesting. While high dosage and prolong use of COX-2 
inhibitors can cause severe side effects like vasodilatation and cardiovascular malfunctions in 
breast cancer patients, EP4 antagonist came as the best alternative of COX-2 inhibitors. 
Moreover, it is highly specific and has been approved by FDA for arthritis treatment119. In 
future, these miRNAs could be used as screening tools for monitoring therapeutic progress. 
3.7 Conclusion 
In conclusion, the above findings show that pri-miR526b and pri-miR655 are well 
secreted in plasma of breast cancer patients. We found that both pri-miRNA expression can 
distinguish early tumor stage 1 from individuals with no evidence of disease. Also, a positive 
correlation of pri-miRNA expression with tumor progression could be seen with more plasma 
samples in progressive tumor stages, as both pri-miRNA markers showed higher expressions 
at the later tumor stages (3&4) than the earlier tumor stage (1). 
Nevertheless, a significant increase and optimum sensitivity of pri-miR655 in plasma at an 
early stage of tumor growth, indicates its potential as a diagnostic biomarker for early detection 
of breast cancer. The recruitment of more patient samples to test the diagnostic value of both 
pri-miR526b and pri-miR655 is encouraged. This will provide an opportunity for a reliable 
blood-based biomarker which could support the currently used screening markers for early 
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diagnosis of breast cancer. Importantly, it will accommodate the pre-screening of younger 
women for early detection of breast cancer.  
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Thesis Summary 
This thesis discussed the discovery of novel roles of miR526b and miR655 in tumor-associated 
angiogenesis and their potential as biomarkers in breast cancer. In the first manuscript, we 
hypothesized that microRNA promotes the secretion of vascular ligands, which attract vascular 
endothelial cells to the tumor site to promote angiogenesis. I showed that both miRNAs 
promote the upregulation of vascular markers of angiogenesis and lymphangiogenesis in 
miRNA high breast cancer cells. Moreover, conditioned media from miRNA high cells, 
containing miRNA secretions, promotes HUVEC functions that are involved in the making of 
new vessels. This suggests that both miRNAs promote angiogenesis via paracrine regulation 
and tumor growth by autocrine regulation. Thus, miR526b and miR655 promote aggressive 
tumor growth and breast cancer progression by making new blood vessels. Here, aggressive 
tumor cells invade the blood vessels and become more accessible in the vasculature, possibly 
as circulating tumor cells to metastasize to other organs. Hence, in the second manuscript, I am 
showing that miRNA can be measured in breast cancer patient’s blood and can be used as blood 
biomarker for cancer detection. Differential expression of miRNA in plasma of patients with 
different tumor stages, indicates that they can also be used to monitor tumor progression or 
treatment progress. 
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Abstract: In eukaryotes, overproduction of reactive oxygen species (ROS) causes oxidative stress,
which contributes to chronic inflammation and cancer. MicroRNAs (miRNAs) are small, endogenously
produced RNAs that play a major role in cancer progression. We established that overexpression
of miR526b/miR655 promotes aggressive breast cancer phenotypes. Here, we investigated the
roles of miR526b/miR655 in oxidative stress in breast cancer using in vitro and in silico assays.
miRNA-overexpression in MCF7 cells directly enhances ROS and superoxide (SO) production,
detected with fluorescence assays. We found that cell-free conditioned media contain extracellular
miR526b/miR655 and treatment with these miRNA-conditioned media causes overproduction
of ROS/SO in MCF7 and primary cells (HUVECs). Thioredoxin Reductase 1 (TXNRD1) is an
oxidoreductase that maintains ROS/SO concentration. Overexpression of TXNRD1 is associated
with breast cancer progression. We observed that miR526b/miR655 overexpression upregulates
TXNRD1 expression in MCF7 cells, and treatment with miRNA-conditioned media upregulates
TXNRD1 in both MCF7 and HUVECs. Bioinformatic analysis identifies two negative regulators of
TXNRD1, TCF21 and PBRM1, as direct targets of miR526b/miR655. We validated that TCF21 and
PBRM1 were significantly downregulated with miRNA upregulation, establishing a link between
miR526b/miR655 and TXNRD1. Finally, treatments with oxidative stress inducers such as H2O2
or miRNA-conditioned media showed an upregulation of miR526b/miR655 expression in MCF7
cells, indicating that oxidative stress also induces miRNA overexpression. This study establishes the
dynamic functions of miR526b/miR655 in oxidative stress induction in breast cancer.
Keywords: MicroRNA (miRNA); miR526b; miR655; oxidative stress; reactive oxygen species (ROS);
superoxide (SO); Thioredoxin Reductase 1 (TXNRD1); breast cancer
1. Introduction
Breast cancer is the most common cancer affecting women and is responsible for the highest
number of cancer-related deaths among women worldwide [1]. Breast cancer progression follows
a complex multistep process, which depends on multiple exogenous and endogenous factors. The
production of reactive oxygen species (ROS) such as superoxide (SO) leads to the induction of oxidative
stress, which has been largely associated with breast cancer [2]. Oxidative stress is the result of
cellular inability to neutralize and eliminate excess ROS, which is frequently associated with cancer
development and progression. Under normal physiological conditions, cells endogenously produce
ROS such as H2O2, ONOO−, OH−, HClO−, NO−, ROO−, and SO, during metabolism, respiration,
and biosynthesis of macromolecules. Thus, cell metabolites are great resources for understanding
Int. J. Mol. Sci. 2019, 20, 4039; doi:10.3390/ijms20164039 www.mdpi.com/journal/ijms
cancers
Article
Mir526b and Mir655 Promote Tumour Associated
Angiogenesis and Lymphangiogenesis in
Breast Cancer
Stephanie Hunter, Braydon Nault †, Kingsley Chukwunonso Ugwuagbo †, Sujit Maiti and
Mousumi Majumder *
Department of Biology, Brandon University, 3rd Floor, John R. Brodie Science Centre, 270–18th Street,
Brandon, MB R7A 6A9, Canada
* Correspondence: majumderm@brandonu.ca
† These authors contributed equally to this work.
Received: 11 June 2019; Accepted: 29 June 2019; Published: 4 July 2019


Abstract: MicroRNAs (miRNAs) are small endogenously produced RNAs, which regulate growth
and development, and oncogenic miRNA regulate tumor growth and metastasis. Tumour-associated
angiogenesis and lymphangiogenesis are processes involving the release of growth factors from
tumour cells into the microenvioronemnt to communicate with endothelial cells to induce vascular
propagation. Here, we examined the roles of cyclo-oxygenase (COX)-2 induced miR526b and miR655
in tumour-associated angiogenesis and lymphangiogenesis. Ectopic overexpression of miR526b and
miR655 in poorly metastatic estrogen receptor (ER) positive MCF7 breast cancer cells resulted in
upregulation of angiogenesis and lymphangiogenesis markers vascular endothelial growth factor A
(VEGFA); VEGFC; VEGFD; COX-2; lymphatic vessel endothelial hyaluronan receptor-1 (LYVE1); and
receptors VEGFR1, VEGFR2, and EP4. Further, miRNA-high cell free conditioned media promoted
migration and tube formation by human umbilical vein endothelial cells (HUVECs), and upregulated
VEGFR1, VEGFR2, and EP4 expression, showing paracrine stimulation of miRNA in the tumor
microenvironment. The miRNA-induced migration and tube formation phenotypes were abrogated
with EP4 antagonist or PI3K/Akt inhibitor treatments, confirming the involvement of the EP4 and
PI3K/Akt pathway. Tumour supressor gene PTEN was found to be downregulated in miRNA
high cells, confirming that it is a target of both miRNAs. PTEN inhibits hypoxia-inducible factor-1
(HIF1α) and the PI3K/Akt pathway, and loss of regulation of these pathways through PTEN results
in upregulation of VEGF expression. Moreover, in breast tumors, angiogenesis marker VEGFA and
lymphangiogenesis marker VEGFD expression was found to be significantly higher compared with
non-adjacent control, and expression of miR526b and miR655 was positively correlated with VEGFA,
VEGFC, VEGFD, CD31, and LYVE1 expression in breast tumour samples. These findings further
strengthen the role of miRNAs as breast cancer biomarkers and EP4 as a potential therapeutic target
to abrogate miRNA-induced angiogenesis and lymphangiogenesis in breast cancer.
Keywords: miR526b; miR655; breast cancer; angiogenesis; lymphangiogenesis; EP4; PI3K/Akt
1. Introduction
Breast cancer is the deadliest and most prevalent cancer among women, being responsible
for the greatest number of cancer-related deaths among women worldwide [1]. In many cancers,
including human breast cancer, cyclo-oxygenase (COX)-2 enzyme is found to have higher than normal
expression [2]. Specifically, upregulation of COX-2 is correlated with breast cancer disease progression,
metastasis, and poor patient survival [3,4]. COX-2 is responsible for the production of the inflammatory
Cancers 2019, 11, 938; doi:10.3390/cancers11070938 www.mdpi.com/journal/cancers 73
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ABSTRACT
Prostaglandin (PG)-E2 is essential for growth and development of
vertebrates. PGE2 binds to G-coupled receptors to regulate embryonic
stem cell differentiation and maintains tissue homeostasis.
Overproduction of PGE2 by breast tumor cells promotes aggressive
breast cancer phenotypes and tumor-associated lymphangiogenesis.
In this study, we investigated novel roles of PGE2 in early embryonic
vascular development and maturation with the microinjection of PGE2 in
fertilized zebrafish (Danio rerio) eggs. We injected Texas Red dextran to
trace vascular development. Embryos injected with the solvent of PGE2
served as vehicle. Distinct developmental changes were noted from 28–
96 h post fertilization (hpf), showing an increase in embryonic tail flicks,
pigmentation, growth, hatching and larval movement post-hatching in the
PGE2-injected group compared to the vehicle. We recorded a significant
increase in trunk vascular fluorescence and maturation of vascular
anatomy, embryo heartbeat and blood vessel formation in the PGE2
injected group. At 96 hpf, all larvaewere euthanized tomeasure vascular
marker mRNA expression. We observed a significant increase in the
expression of stem cell markers efnb2a, ephb4a, angiogenesis markers
vegfa,kdrl,etv2and lymphangiogenesismarkerprox1 in thePGE2-group
compared to the vehicle. This study shows the novel roles of PGE2 in
promoting embryonic vascularmaturation and angiogenesis in zebrafish.
Thisarticle hasanassociatedFirst Person interviewwith the first authorof
the paper.
KEY WORDS: Zebrafish, Prostaglandin E2 (PGE2), Vascular
development and maturation, Angiogenesis
INTRODUCTION
Prostaglandin (PG) E-2 is a prostanoid, which is endogenously
synthesized from the arachidonic acid of vertebrate cellmembranes by
an enzyme, cyclooxygenase (COX)-2. PGE2 binds to four different
G-coupled receptors (EPs), EP 1–4, which have various cellular
functions (Sugimoto and Narumiya, 2007). EP2 and EP4 receptors
share the cAMP/PKA pathway; however, EP4 additionally signals
through the phosphatidylinositol 3-kinase (PI3K)/AKT pathway
(Fujino et al., 2003). In vertebrates, PGE2 plays major
physiological roles in embryonic development by regulating the
homeostatic balance of hematopoietic stem cells (HSC) during early
embryonic growth. The role of PGE synthase (Ptges) in embryonic
differentiation and growth in zebrafish was well investigated by Cha
et al. (2006). They showed that knockdown of Ptges in the zebrafish
embryo completely abrogated early cell differentiation and cell
polarization, which was retrieved with PGE2 addition, as embryos
could recover all phenotypes. They have also shown that PGE2
regulates zebrafish growth via EP4/PI3K/Akt pathways (Cha et al.,
2006). Supporting this, North et al. (2007) showed that PGE2
regulates the differentiation of embryonic stem cells. This study
showed that treatment with chemicals that enhance PGE2 synthesis
induced HSC and in contrast, chemicals, which block prostaglandin
synthesis, decreased stem cell numbers (North et al., 2007).
PGE2 induces breast cancer stem-like cells (SLCs) via the
upregulation of stem cells marker (NANOG and SOX2) in tumors
and by stimulation of NOTCH andWnt genes expression (Majumder
et al., 2016). With a COX-2 inhibitor (COX2-I) and specific EP4
antagonist (EP4A) treatment, we could abrogate COX-2/PGE2
induced SLCs in breast cancer. In addition, PI3K/Akt inhibitors also
abrogated PGE2 induced NOTCH and WNT genes expression in
human breast cancer. Therefore, we have established that COX-2 and
PGE2 induce human breast SLCs and were regulated by EP4/PI3K/
Akt/NOTCH/WNT pathways (Majumder et al., 2016). However, we
never tested the roles of PGE2 in vertebrate vascular development.
Zebrafish arewidely used as vertebratemodels for pathophysiological
studies (North et al., 2007;Zon andPeterson, 2005). The transparencyof
the zebrafish identifies it as agoodmodel for the investigationofvascular
development. Moreover, zebrafish mutually share many structural,
functional and molecular features with other vertebrates and are perfect
models for xenotransplantation due to their inability to reject graftwithin
48 hpf (Benyumov et al., 2012; Jung et al., 2017; Mulligan and
Weinstein, 2014). In vertebrates, lymphangiogenesis begins from HSC
fate determination, through several differentiation steps to develop
arterial and venous progenitors (Nicenboim et al., 2015). The genetic
interactions involving HSC homeostasis and replenishment in zebrafish
is regulated by PGE2 through theWnt pathway (Goessling et al., 2009).
Similarly, cardiac muscle development and pigmentation in zebrafish
was shown to be regulated throughWnt signaling (Dohn andWaxman,
2012; Vibert et al., 2017). In animal models, cell lineage and vascular
differentiation stages could be monitored with Texas Red low-
molecular-weight dextran, a widely used fluorescent dye for tracing
vascular lineages in vertebrate development (Zhao et al., 2011). There is
no comprehensive report on the roles of PGE2 in zebrafish embryonic
angiogenesis and lymphangiogenesis. Therefore in this study, we
investigated the effects of PGE2 on zebrafish embryonic vascular
development and maturation.
The process of vascular development and maturation principally
involves the interaction of vascular endothelial growth factors (vegf)s
with their cognate receptors (vegfr)s in zebrafish. VEGF/VEGFR
interaction plays a critical role in the formation and modification ofReceived 26 October 2018; Accepted 28 February 2019
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Abstract: G-protein-coupled receptors (GPCRs, also called seven-transmembrane or heptahelical
receptors) are a superfamily of cell surface receptor proteins that bind to many extracellular
ligands and transmit signals to an intracellular guanine nucleotide-binding protein (G-protein).
When a ligand binds, the receptor activates the attached G-protein by causing the exchange of
Guanosine-5′-triphosphate (GTP) for guanosine diphosphate (GDP). They play a major role in many
physiological functions, as well as in the pathology of many diseases, including cancer progression
and metastasis. Only a few GPCR members have been exploited as targets for developing drugs with
therapeutic benefit in cancer. Present review briefly summarizes the signaling pathways utilized
by the EP (prostaglandin E receptor) family of GPCR, their physiological and pathological roles in
carcinogenesis, with special emphasis on the roles of EP4 in breast cancer progression. We make a case
for EP4 as a promising newer therapeutic target for treating breast cancer. We show that an aberrant
over-expression of cyclooxygenase (COX)-2, which is an inflammation-associated enzyme, occurring
in 40–50% of breast cancer patients leads to tumor progression and metastasis due to multiple cellular
events resulting from an increased prostaglandin (PG) E2 production in the tumor milieu. They
include inactivation of host anti-tumor immune cells, such as Natural Killer (NK) and T cells, increased
immuno-suppressor function of tumor-associated macrophages, promotion of tumor cell migration,
invasiveness and tumor-associated angiogenesis, due to upregulation of multiple angiogenic factors
including Vascular Endothelial Growth Factor (VEGF)-A, increased lymphangiogenesis (due to
upregulation of VEGF-C/D), and a stimulation of stem-like cell (SLC) phenotype in cancer cells.
All of these events were primarily mediated by activation of the Prostaglandin (PG) E receptor
EP4 on tumor or host cells. We show that selective EP4 antagonists (EP4A) could mitigate all of
these events tested with cells in vitro as well as in vivo in syngeneic COX-2 expressing mammary
cancer bearing mice or immune-deficient mice bearing COX-2 over-expressing human breast cancer
xenografts. We suggest that EP4A can avoid thrombo-embolic side effects of long term use of
COX-2 inhibitors by sparing cardio-protective roles of PGI2 via IP receptor activation or PGE2
via EP3 receptor activation. Furthermore, we identified two COX-2/EP4 induced oncogenic and
SLC-stimulating microRNAs—miR526b and miR655, one of which (miR655) appears to be a potential
blood biomarker in breast cancer patients for monitoring SLC-ablative therapies, such as with EP4A.
We suggest that EP4A will likely produce the highest benefit in aggressive breast cancers, such as
COX-2 expressing triple-negative breast cancers, when combined with other newer agents, such as
inhibitors of programmed cell death (PD)-1 or PD-L1.
Int. J. Mol. Sci. 2018, 19, 1019; doi:10.3390/ijms19041019 www.mdpi.com/journal/ijms 75
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